Immunogenic compositions comprising Lawsonia intracellularis

ABSTRACT

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by  L. intracellularis , and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by  L. intracellularis , and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

BACKGROUND

The present invention relates to combination vaccines or multivalentvaccines comprising Lawsonia intracellularis (L. intracellularis)antigen and at least one further antigen of one or more swine pathogensother than L. intracellularis. More particularly, the present inventionprovides immunogenic compositions effective at inducing an immuneresponse against infection by L. intracellularis and at least one otherdisease-causing organism for swine.

L. intracellularis, the causative agent of porcine proliferativeenteropathy (“PPE”), affects virtually all animals, including: rabbits,ferrets, hamsters, fox, horses, and other animals as diverse asostriches and emus. PPE is a common diarrheal disease ofgrowing-finishing and young breeding pigs characterized by hyperplasiaand inflammation of the ileum and colon. It often is mild andself-limiting but sometimes causes persistent diarrhea, severe necroticenteritis, or hemorrhagic enteritis with high mortality.

The bacteria associated with PPE have been referred to as“Campylobacter-like organisms.” S. McOrist et al., Vet. Pathol., Vol.26, 260-264 (1989). Subsequently, the causative bacteria have beenidentified as a novel taxonomic genus and species, vernacularly referredto as Ileal symbiont (IS) intracellularis. C. Gebhart et al., Int'l. J.of Systemic Bacteriology, Vol. 43, No. 3, 533-538 (1993). More recently,these novel bacteria have been given the taxonomic name Lawsonia (L.)intracellularis. S. McOrist et al., Int'l. J. of Systemic Bacteriology,Vol. 45, No. 4, 820-825 (1995). These three names have been usedinterchangeably to refer to the same organism as further identified anddescribed herein. Koch's postulates have been fulfilled by inoculationof pure cultures of L intracellularis into conventionally reared pigs;typical lesions of the disease were produced, and L intracellularis wasreisolated from the lesions. The more common, nonhemorrhagic form of thedisease often affects 18- to 36-kg pigs and is characterized by suddenonset of diarrhea. The feces are watery to pasty, brownish, or faintlyblood stained. After ˜2 days, pigs may pass yellow fibrinonecrotic caststhat have formed in the ileum. Most affected pigs recover spontaneously,but a significant number develop chronic necrotic enteritis withprogressive emaciation. The hemorrhagic form is characterized bycutaneous pallor, weakness, and passage of hemorrhagic or black, tarryfeces. Pregnant gilts may abort. Lesions may occur anywhere in the lowerhalf of the small intestine, cecum, or colon but are most frequent andobvious in the ileum. The wall of the intestine is thickened, and themesentery may be edematous. The mesenteric lymph nodes are enlarged. Theintestinal mucosa appears thickened and rugose, may be covered with abrownish or yellow fibrinonecrotic membrane, and sometimes has petechialhemorrhages. Yellow necrotic casts may be found in the ileum or passingthrough the colon. Diffuse, complete mucosal necrosis in chronic casescauses the intestine to be rigid, resembling a garden hose.Proliferative mucosal lesions often are in the colon but are detectedonly by careful inspection at necropsy. In the profusely hemorrhagicform, there are red or black, tarry feces in the colon and clotted bloodin the ileum. Altogether, L. intracellularis is a particularly greatcause of losses in swine herds in Europe as well as in the UnitedStates.

L. intracellularis is an obligate, intracellular bacterium which cannotbe cultured by normal bacteriological methods on conventional cell-freemedia and has been thought to require cells for growth. S. McOrist etal., Infection and Immunity, Vol. 61, No. 19, 4286-4292 (1993) and G.Lawson et al., J. of Clinical Microbiology, Vol. 31, No. 5, 1136-1142(1993) discuss cultivation of L. intracellularis using IEC-18 ratintestinal epithelial cell monolayers in conventional tissue cultureflasks. In U.S. Pat. Nos. 5,714,375 and 5,885,823, both of which patentsare herein incorporated by reference in their entireties, cultivation ofL. intracellularis in suspended host cells was described.

Pathogenic and non-pathogenic attenuated bacteria strains of L.intracellularis are well known in state of the art. For example, WO96/39629 and WO 05/011731 describe non-pathogenic attenuated strains ofL. intracellularis. Further attenuated bacteria strains of L.intracellularis are known from WO 02/26250 and WO 03/00665.

Actinobacillus pleuropneumonia, also known as APP and Haemophiluspleuropneumonia, is caused by the Actinobacillus pleuopneumoniabacteria. There are currently 15 serovars described and the severity ofthe clinical signs differ between the different serovirus and thepresence of other factors. Serovirus 1, 5, 9, 10, and 11 are consideredto be more virulent. Additionally, serovirus 1, 9, and 11; 2, 6, and 8;and 4 and 7 may cross-react. Pigs of all ages are susceptible. Clinicalsigns are a sudden illness that results in animals lying down a lot andpresenting a high rectal temperature of 41.5° Celsius. Animals aregenerally anorexic and do not drink, their extremities become cyanoticand cold to the touch. Cyanosis can spread to the whole body and severebreathing difficulties, often with mouth breathing, develop beforedeath. Blood-stained froth can be seen at the mouth and nostrils anddeath generally occurs within 24-48 hours. Acute clinical signs includea high percentage of animals in a group being depressed and lying down,high rectal temperatures of 40.5-41° Celsius, anorexia, lack ofdrinking, severe respiratory distress, coughing, mouth breathing,cyanosis, vomiting, and abortion. Sub-acute clinical signs includeintermittent coughing in a group of pigs, a general loss of appetite,and a reduction in growth. Cyrovar type 3 presents with arthritis,endocarditis, and abscesses. In chronically effected herds, daily weightgain may not be affected, but an intermittent cough may be heard.

Bordetella bronchiseptica Infection: Asymptomatic pigs may harbor thisgram-negative, nonsporeforming rod in the nasal cavity and trachea.Subclinical infections are more common in colonies, but epizooticoutbreaks can occur rapidly with high morbidity and mortality.Transmission is by aerosol or, in its genital form, through sexualcontact. Genital infection may cause infertility, stillbirths, andabortions. Several other species may be asymptomatic upper respiratorycarriers, including dogs, cats, rabbits, rats, and mice. Contact withthese potential hosts should be avoided. Necropsy may reveal lungconsolidation and mucopurulent exudate in the bronchi, trachea, andmiddle ear.

Spirochaetal colitis is caused by the Brachyspira pilosicoli bacteria.This infection generally affects 10-20 week old growers/finishers. It ischaracterized by a non-fatal wasting diarrhea of growing pigs thatresults in an increased number of days needed to finish. The diarrheaalso results in reduction in feed efficiency and produces waterydiarrhea or loose stools. About half of the pigs may show transient topersistent, to watery to mucoid green to brownish diarrhea, withoutblood. The clinical signs are more common 10-14 days after mixing andchanging of the feed. Swine dysentery is caused by the bacteriaBrachyspira hyodysentheriae. There are twelve known sero-types at thistime. Clinical signs in established herd include diarrhea, a rapid lossof condition in some pigs, a hairy appearance, dehydration, painfulabdomen, and the death of one or two pigs before other pigs show anysigns. In a key outbreak in naïve herds, all age groups from sucklingpiglets to adult sows can be effected.

Brucellosis is caused by bacteria of the genus Brucella and ischaracterized by abortion, retained placenta, infertility, orchitis inboars and severe metritis in sows. In piglets, the disease ischaracterized by posterior paralysis and lameness. The disease in pigsis caused almost exclusively by Brucella suis biovars 1, 2, and 3. Anumber of other mammals can carry and transmit Brucella suis to pigs.Infection spreads rapidly and causes many abortions in unvaccinatedherds. Transmission occurs mainly by contact with another pig, althoughvenereal transmission is possible. Serological diagnosis can bedifficult due to a relatively common organism, Yersinia enterocoliticaO:9 which shares a common antigen with Brucella and often causes falsepositive results. Post-mortem lesions usually include metritis andorchitis, and can include abscessation, sometimes with necorsis foci inthe liver.

Porcine Epidemic Diarrhea (PED) is caused by a coronavirus somewhatsimilar to that which causes TGE. This virus is widespread in Europe.The virus damages the villi in the gut thus reducing the absorptivesurface, with attendant loss of fluid and dehydration. Afterintroduction of the virus into a susceptible breeding herd, a strongimmunity develops over two to three weeks. The colostral immunity thenprotects the piglets. The virus usually disappears spontaneously frombreeding herds particularly small ones (<300 sows). Acute outbreaks ofdiarrhea occur when the virus is first introduced into a susceptiblepopulation. In such cases up to 100% of sows may be affected, showing amild to very watery diarrhea. Two clinical pictures are recognized: PEDType I only affects growing pigs whereas PED Type II affects all agesincluding sucking pigs and mature sows. The incubation period isapproximately 2 days and diarrhea lasts for 7 to 14 days. In suckingpigs the disease can be mild or severe with mortalities up to 40%. Inlarge breeding herds, particularly if kept extensively, not all thefemales may become infected the first time around and there may berecrudescence. This only occurs in piglets suckling from sows with nomaternal antibodies and is therefore sporadic.

Clostridium is a ubiquitous gram-positive bacteria, of the familyclostridiaceae, usually found in the soil, but which also occursnaturally in the gut of most animals. C. difficile infections in swineare characterized by severe mesocolonic edema, diarrhea, and edema inother tissues such as the hydrothorax. Clostridium enteritis in swine iscaused by C. perfringens, and is characterized by chronic enteritis,which is accompanied by diarrhea, weight loss and fever. Infection withC perfringens types A, B and C causes severe enteritis, dysentery,toxemia, and high mortality in young calves. Types B and C both producethe highly necrotizing and lethal β toxin that is responsible for thesevere intestinal damage. This toxin is sensitive to proteolyticenzymes, and disease is associated with inhibition of proteolysis in theintestine. Sow colostrum, which contains a trypsin inhibitor, has beensuggested as a factor in the susceptibility of young piglets. Thedisease can cause sudden death in piglets less than one week old, and ismost common within 3 days of birth. In older piglets, Clostridiumenteritis causes a thickening of the small intestine making absorptionof food and nutrients difficult. Piglets usually die as a result of acombination of the infection and lack of nutrients. Death may occur in afew hours, but less severe cases survive for a few days, and recoveryover a period of several days is possible. Hemorrhagic enteritis withulceration of the mucosa is the major lesion in all species. Grossly,the affected portion of the intestine is deep blue-purple and appears atfirst glance to be an infarction associated with mesenteric torsion.Smears of intestinal contents can be examined for large numbers ofgram-positive, rod-shaped bacteria, and filtrates made for detection oftoxin and subsequent identification by neutralization with specificantiserum. Clostridium novyi has been suspected but not yet confirmed asa cause of sudden death in cattle and pigs fed high-level grain diets,and in which pre-existing lesions of the liver were not detectable. Thelethal and necrotizing toxins (primarily α toxin) damage hepaticparenchyma, thereby permitting the bacteria to multiply and produce alethal amount of toxin. Usually, death is sudden with no well-definedsigns. Affected animals tend to lag behind the herd, assume sternalrecumbency, and die within a few hours. Most cases occur in the summerand early fall when liver fluke infection is at its height. The diseaseis most prevalent in 1- to 4-yr-old sheep and is limited to animalsinfected with liver flukes. Differentiation from acute fascioliasis maybe difficult, but peracute deaths of animals that show typical lesionson necropsy should arouse suspicion of infectious necrotic hepatitis.The most characteristic lesions are the grayish yellow necrotic foci inthe liver that often follow the migratory tracks of the young flukes.Other common findings are an enlarged pericardial sac filled withstraw-colored fluid, and excess fluid in the peritoneal and thoraciccavities. Usually, there is extensive rupture of the capillaries in thesubcutaneous tissue, which causes the adjacent skin to turn black (hencethe common name, black disease). Clostridium septicum is found in soiland intestinal contents of animals (including man) throughout the world.Infection ordinarily occurs through contamination of wounds containingdevitalized tissue, soil, or some other tissue-debilitant. Wounds causedby accident, castration, docking, insanitary vaccination, andparturition may become infected. General signs, such as anorexia,intoxication, and high fever, as well as local lesions, develop within afew hours to a few days after predisposing injury. The local lesions aresoft swellings that pit on pressure and extend rapidly because of theformation of large quantities of exudate that infiltrates thesubcutaneous and intramuscular connective tissue of the affected areas.Accumulations of gas are uncommon Malignant edema associated withlacerations is characterized by marked edema, severe toxemia, and deathin 24-48 hr. Tetanus toxemia is caused by a specific neurotoxin producedby Clostridium tetani in necrotic tissue. Almost all mammals, includingswine, are susceptible to this disease. Although tetanus is worldwide indistribution, there are some areas, such as the northern Rocky Mountainsection of the USA, where the organism is rarely found in the soil andwhere tetanus is almost unknown. In general, the occurrence of C tetaniin the soil and the incidence of tetanus in man is higher in the warmerparts of the various continents. Clostridium tetani, an anaerobe withterminal, spherical spores, is found in soil and intestinal tracts. Inmost cases, it is introduced into the tissues through wounds,particularly deep puncture wounds that provide a suitable anaerobicenvironment.

Escherichia coli is a bacteria of the enterbacteriaceae family and isone of the main types of bacteria naturally occurring in the smallintestines of all mammals. Although usually harmless, some E colistrains can produce a number of exo- and endotoxins that cause infectionand disease. Heat-labile (LT) and heat-stable (ST) exotoxins areactively produced by some strains and are responsible for causing scour.Shigela-like toxin type II variant (SLT-IIe), Stx2e and verotoxin edemadisease act on the wall of the small arteries resulting in oedema.Endotoxins, such as Lipid A, play a role in mastitis and urinary tractinfections. E. coli infection is characterized by a number of differentsymptoms depending on the particular strain involved, includingdiarrhea, sunken eyes, unthriftiness, visible weight loss, stuntedgrowth, depression, bowel edema, mastitis, cystitis, pyelonephritis anddeath. E. coli can be classified and coded by their cell wall (Oantigens) and fimbriae (F antigens). For example, scour is oftenassociated with E. coli Abbotstown: O147, F4, F5, whereas bowel edema isassociated with F18 fimbriae. Correctly identifying the code isessential to the selection of the correct vaccine. E. coli infectionscompromise a pig's immune system and deaths are often the result ofsecondary infections and disease.

Encephalomyocarditis, or EMC, infects and causes disease in a wide rangeof vertebrate animals but pigs appear to be the most susceptible of farmanimal species. The virus, Encephalomyocarditis virus is world-wide butdiffers in pathogenicity and virulence in different countries andregions. In most countries of Europe, particularly those in the EU, ittends to be relatively mild or non-pathogenic and disease in pigs israrely diagnosed. In Australia the strains appear to be much morevirulent for pigs than those in New Zealand. Virulent strains inFlorida, the Caribbean and probably Central America damage the heart andcause death whereas those in the Mid-West of the US tend to causereproductive problems. Clinical disease in pigs tends to occur when ratnumbers increase to plague levels. Pigs can be infected from rats orfrom rat-contaminated feed or water. It does not seem to spread veryreadily between pigs. In affected herds there are usually no clinicalsigns in weaned and growing pigs.

Eperythrozoonosis is a Rickettsial (haemotrophic) disease caused byEperythrozoon suis, an extracellular bacterial organism that adheres topig erythrocyte membranes, inducing its deformation and damage. Thedisease is characterized by anemia and icterus (yellow discoloration ofmucous membranes, sclera and inner ears). It can lead to poor conceptionrates, other vague reproduction problems and even death.

Swine erysipelas is caused by a bacterium, Erysipelothrix rhusiopathiaethat is found in most if not all pig farms. Up to 50% of animals maycarry it in their tonsils. It is always present in either the pig or inthe environment because it is excreted via saliva, feces or urine. It isalso found in many other species, including birds and sheep and cansurvive outside the pig for a few weeks and longer in light soils. Thusit is impossible to eliminate it from a herd. Infected feces areprobably the main source of infection, particularly in growing andfinishing pens. The bacterium alone can cause the disease but concurrentvirus infections, such as PRRS or influenza, may trigger off outbreaks.Disease is relatively uncommon in pigs under 8-12 weeks of age due toprotection provided by maternal antibodies from the sow via thecolostrum. The most susceptible animals are growing pigs, non-vaccinatedgilts and up to 4th parity sows. The organism multiplies in the body,and invades the bloodstream to produce a septicemia. The rapidity ofmultiplication and the level of immunity in the pig then determines theclinical symptoms.

Glässers Disease is caused by the bacterium Haemophilus parasuis (Hps),of which there are at least fifteen different types. It is foundthroughout the world and organisms are present even in high healthherds. If such herds are set up using SPF or MEW techniques and are freefrom Hps it can be devastating when they first become contaminated,producing an anthrax-like disease with high mortality in sows. In themajority of herds in which the bacterium is endemic, sows produce astrong maternal immunity which normally persists in their offspringuntil 8 to 12 weeks of age. As a result, the effects of the infection inweaners are usually nil or minimal. Disease may however be seen insuckling pigs. Pigs usually become sub-clinically infected when stillprotected by maternal antibody and then stimulate their own immuneresponse. If however, the maternal immunity wears off before they becomeinfected they may develop severe disease. This is usually sometime afterweaning. It can also act as a secondary pathogen to other major diseasesparticularly enzootic pneumonia (EP) (Mycoplasma hyopneumoniae).Outbreaks of disease are sometimes experienced in sucking pigs,particularly in gilt herds. Hps attacks the smooth surfaces of thejoints, coverings of the intestine, lungs, heart and brain, causingpneumonia, heart sac infection, peritonitis and pleurisy. It isrespiratory spread. Disease caused by Hps is rare in sows unless the drysow is naïve. Lameness or stiffness, slight swellings over the jointsand tendons, and rarely meningitis, are occasionally seen in gilts. Inpiglets, acute disease presents with rapidly depressed pigs withelevated temperature, inappetence, and a reluctance to rise. Onecharacteristic feature is a short cough of 2-3 episodes. Sudden death ingood sucking piglets is not uncommon. Hps is also known to causeindividual cases of arthritis and lameness with fever and inappetence.Chronic disease is characterized by pale and poor growing pigs. Suddendeath may also occur. For weaners and growers, pigs with GlässersDisease become rapidly depressed or may be just found dead. Othersymptoms include elevated temperature, anorexia, a reluctance to rise,nervous signs such as fits and convulsions including meningitis, andpoor pigs, that are wasting and hairy often result. In young growingpigs, the following symptoms are most common: fever, mild meningitis,arthritis, lameness, pneumonia, heart sac infection, peritonitis andpleurisy. Again, a characteristic feature is a short cough of only 2-3episodes.

Leptospirosis is a contagious disease of animals, including man, causedby various immunologically distinct leptospiral serovars, most of whichare regarded as subgroups of Leptospira interrogans. There are fiveserovars and groups which are important in swine: pomona, australis,tarassovi, canicola, icterohaemorrhagicae, and grippotyphosa. Infectionsmay be asymptomatic or cause various signs, including anorexia, pyrexia,listlessness, jaundice, abortions, still births and other vaguereproductive problems, and death. After acute infection, leptospiresfrequently localize in the kidneys or reproductive organs consisting ofscattered small grey foci of a focal interstitial nephritis, and areshed in the urine, sometimes in large numbers for months or years.Because the organisms survive in surface waters for extended periods,the disease is often waterborne. In the USA, the disease is primarilydue to the serovars Leptospira hardjo, Leptospira pomona, and Leptospiragrippotyphosa. Diagnosis can be difficult because antibody titers can betransient, lasting less than a month. Further, Leptospira can also befound in healthy animals. L. australis serovar bratislava is mostcommonly associated with reproductive problems. Chronically infectedherds display abortions, still births and weak piglets.

Tuberculosis affects mammals, including people, birds, and swine. Thecausal organism, Mycobacterium tuberculosis, is sub-classified intotypes, human, bovine and avian. The avian type is referred to as M.avium or more often the avian/intracellulare complex because it is not auniform species. M. avium itself infects mainly birds but is also foundin the environment along with M. intracellulare which is predominantlysaprophytic or free living. Pigs are rarely infected by the human orbovine types but are commonly infected by the avian/intracellularecomplex. The avian/intracellulare complex also causes sub-clinicalnon-progressive infection in healthy people. The main concern is that itcould cause more serious disease in immuno-suppressed people and peoplewith AIDS. In most countries if lesions are found in the neck atslaughter the whole head is condemned and if they are found in themesenteric lymph nodes which drain the intestines the offals arecondemned. If they are more widespread in the body, which is rare, thewhole carcass may be condemned or cooked. If small lesions are missed bythe meat inspector normal kitchen cooking destroys the organism. In allpigs, infection causes small nodules in the lymph nodes of the neck andthose that drain the small intestine. In the great majority of cases thelesions are non-progressive, they do not spread through the body, do notmake the pig ill and are not excreted. There are no clinical symptomsand there is no difference in performance between infected andnon-infected pigs.

Mycoplasma hyopneumoniae (M hyo) is a small bacterium (400-1200 nm)classified in the mycoplasmataceae family. M hyo is associated withEnzootic Pneumonia, a swine respiratory disease commonly seen in growingand finishing pigs. M hyo attacks the cilia of epithelial cells of thewindpipe and lungs, causing the cilia to stop beating (ciliostasis) andeventually causing areas of the lungs to collapse. Depending on theextent of the disease, daily live weight gain of infected swine can bereduced by up to 17%. Enzootic Pneumonia is widespread in swinepopulations and present in almost every swine herd. M hyo is consideredto be a primary pathogen that facilitates entry of PRRSV and otherrespiratory pathogens into the lungs. Three separate strains, 232, J &7448 have had their genomes sequenced (Minion et al., J. Bacteriol. 186:7123-33, 2004; Vasconcelos et al., J. Bacteriol. 187: 5568-77, 2005).

Parvovirus is a disease characterized by reproductive problems in pigs.The causal agent is a small DNA non-enveloped virus. Fetuses are theonly affected group and the effect on the fetus depends upon the age atwhich it becomes infected. At 10-30 days of age, infection results indeath and reabsorption of the fetus. Between 30-70 days of age,infection results in death and mummification. And from 70 days to term,infection results in the birth of weak piglets and mummification. Thedisease is able to cross the placenta and then move to each fetus alongthe uterus. In the sow, the clinical signs are still births, mummifiedpiglets, embryonic deaths, infertility, and the production of asignificantly reduced number of live-born offspring. Abortion is not acharacteristic feature of parvovirus infection.

Pneumonic pasteurellosis is caused by Pasteurella multocida. Infectionby the causal agent generally represents the final stage of thepost-weaning respiratory syndrome. Clinical signs appear in three forms,the acute form is most commonly associated with P. multocida serotype B.Animals present with dyspnea, labored breathing, thumping, high fever(42.2 Celsius), prostration, and finally death. In some cases theabdomen becomes purple with discoloration. A second form is a sub-acuteform characterized by pleuritis, coughing, and difficulty in breathing.Pigs can lose significant amounts of weight and may have poor or nogrowth with serious consequences in pig flow. The chronic form presentswith the occasional cough, thumping, and little or no fever. This formgenerally affects pigs from 10-16 weeks of age.

Porcine circovirus is a small (17-22 nm in diameter), icosahedral,non-enveloped DNA virus, which contains a single-stranded circulargenome. Porcine circovirus type 2 PCV2 shares approximately 80% sequenceidentity with porcine circovirus type 1 (PCV1). However, in contrastwith PCV1, which is generally non-virulent, swine infected with PCV2exhibit a syndrome commonly referred to as Post-weaning MultisystemicWasting Syndrome (PMWS). PMWS is clinically characterized by wasting,paleness of the skin, unthriftiness, respiratory distress, diarrhea,icterus, and jaundice. In some affected swine, a combination of allsymptoms will be apparent while other swine will only have one or two ofthese symptoms. During necropsy, microscopic and macroscopic lesionsalso appear on multiple tissues and organs, with lymphoid organs beingthe most common site for lesions. A strong correlation has been observedbetween the amount of PCV2 nucleic acid or antigen and the severity ofmicroscopic lymphoid lesions. Mortality rates for swine infected withPCV2 can approach 80%.

Porcine Reproductive and Respiratory Syndrome (PRRS) is caused by avirus which was first isolated and classified as an arterivirus asrecently as 1991. The disease syndrome had been first recognized in theUSA in the mid 1980's and was called “mystery swine disease”. It hasalso been called blue ear disease. The name porcine arterivirus has beenproposed recently. The virus of PRRS has a particular affinity for themacrophages particularly those found in the lung. Macrophages are partof the body defenses. Those present in the lung are called alveolarmacrophages. They ingest and remove invading bacteria and viruses, butnot in the case of the PRRS virus. Instead, the virus multiplies insidethem producing more virus and killing the macrophages. Once it hasentered a herd it tends to remain present and active indefinitely. Up to40% of the macrophages are destroyed which removes a major part of thebody's defense mechanism and allows bacteria and other viruses toproliferate and do damage. A common example of this is the noticeableincrease in severity of enzootic pneumonia in grower/finisher units whenthey become infected with PRRS virus. It may take up to a year for allbreeding stock, particularly in large herds, to become infected for thefirst time and although the virus appears to spread rapidly in a herd itmay be some 4-5 months before at least 90% of the sows have becomesero-positive. Some sows remain naive. Furthermore, it is not uncommonfor sow herds 1-2 years after infection to contain less than 20% ofserological positive animals. This does not however necessarily meanthey are not still immune nor does it mean that they have stoppedpassing on immunity to their offspring. Adult animals shed virus formuch shorter periods of time (14 days) compared to growing pigs whichcan excrete for 1-2 months. The clinical picture can vary tremendouslyfrom one herd to another. As a guide, for every three herds that areexposed to PRRS for the first time, one will show no recognizabledisease, the second would show mild disease and the third, moderate tosevere disease. The reasons for this are not clearly understood. Howeverthe higher the health status of the herd, the less severe are thedisease effects. It may be that the virus is mutating as it multiplies,throwing up some strains that are highly virulent and some that are not.PRRS infects all types of herds including ones with high or ordinaryhealth status and both indoor and outdoor units, irrespective of size.

Pseudorabies, also known as porcine rabies virus, or Suid herpes virusin which the causal agent is an enveloped herpes DNA virus. In naïveherds, neonatal pigs present with a range of severe central nervoussigns from fitting to severe in coordination. Posterior paralysis mayresult in piglets sitting in a manner that resembles dogs. Additionally,mortality is high. In weaned pigs, the central nervous signs may bereduced, but may be accompanied by an increase in respiratory signs.Oftentimes, respiratory diseases are associated with secondaryinfections. Weaned pigs can waste and suffer ill thrift and are oftenstunted. In growing pigs, the central nervous signs continue to reducewhile the respiratory signs increase. The degree of respiratory diseasedepends on the presence and severity of secondary infections. In adults,reproductive signs predominate. Sows may abort and animals infectedclose to term are likely to give birth to stillborn or weak piglets. Inestablished herds, there may be few clinical signs.

Rotavirus infection is a virus infection that is widespread in pigpopulations. It is present in most if not all pig herds with virtually a100% sero-conversion in adult stock. A further epidemiological featureis its persistence outside the pig where it is resistant toenvironmental changes and many disinfectants. Maternal antibodiespersist for 3-6 weeks after which pigs become susceptible to infectionbut exposure does not necessarily result in disease. It is estimatedthat only 10-15% of diarrheas in pigs are initiated by a primaryrotavirus infection. In a mature herd disease appears after piglets are7 to 10 days of age. It becomes progressively less important with age.However if pathogenic strains of E. coli are present, severe disease canoccur with heavy mortality.

Infection with Salmonella spp can produce diarrhea in animals of allages, especially those that are stressed, closely stocked, or exposed toa heavily contaminated feed or water supply. Salmonellosis is caused bymany species of salmonellae and characterized clinically by one or moreof three major syndromes—septicemia, acute enteritis, and chronicenteritis. The incidence has increased with the intensification oflivestock production. Although various types of Salmonella can causeinfections in pigs, the classic salmonellas found in swine are S.choleraesuis and S. typhimurium. Their resulting clinical patterns ofmost salmonella are not distinct and different species of salmonellaetend to differ in their epidemiology. Plasmid profile anddrug-resistance patterns are sometimes useful markers for epidemiologicstudies. Septicemic salmonellosis is often associated with Scholeraesuis. Infected piglets demonstrate a reluctance to move,anorexia, a high fever of 40.5 C-41.6 C, and may have a shallow cough.Piglets may also be found dead with cyanotic extremities. S choleraesuisis one of the rare diseases that can cause both pneumonia and diarrheaand mortality of infected piglets is often high. Enterocolitis isgenerally associated with the more common S typhimurium. Infections arecharacterized by yellow or watery diarrhea that may contain blood ormucus as the infection progresses. Mortality is low and often associatedwith dehydration and potassium deficiency from the diarrhea. Feces ofinfected animals can contaminate feed and water, fresh and processedmeats from abattoirs, plant and animal products used as fertilizers orfeedstuffs, pasture and rangeland, and many inert materials. Although Scholeraesuis is rarely found in feed. It can also be passed directlyfrom contact with an infected animal. Salmonella can survive for monthsin wet, warm areas such as in feeder pig barns or in water dugouts.Rodents and wild birds also are sources of infection. The prevalence ofinfection varies among species and countries and is much higher than theincidence of clinical disease, which is commonly precipitated bystressful situations such as sudden deprivation of feed, transportation,drought, crowding, parturition, and the administration of some drugs.

Exudative epidermitis is caused by the bacterium Staphylococcus hyicuswhich lives normally on the skin without causing disease. It is notknown why sometimes it flares up and causes a dermatitis which oozesgreasy fluid. It produces toxins which are absorbed into the system anddamage the liver and kidneys. In the sucking piglet disease, is usuallyconfined to individual animals, but it can be a major problem in newgilt herds and weaned pigs. During the days immediately precedingfarrowing, the bacterium multiples profusely in the sow's vagina so thatpiglets are infected during the birth process or soon after. Symptoms insows include uncommon but localized lesions that may be seenparticularly behind the face and eyes. Severely affected piglets willdie. In piglets, symptoms include localized lesions on the flanks andbehind ears. Lesions usually commence with small, dark, localized areasof infection around the face or on the legs. The skin along the flanksthe belly and between the legs changes to a brown color graduallyinvolving the whole of the body. The skin becomes wrinkled with flakingof large areas and it has a greasy feel. In severe cases the skin turnsblack due to necrosis and the piglets die. A more localized picture isseen if the sow has passed some immunity to the piglet, with smallcircumscribed lesions approximately 5-10 mm in diameter that do notspread. For weaners and growers, symptoms usually commence about 3 daysafter weaning with localized, brown areas of infection or dermatitisaround the face or on the legs, where the skin has been damaged. It mayulcerate. The skin along the flanks the belly and between the legschanges to a brown color gradually involving the whole of the body. Theskin becomes wrinkled with flaking of large areas and progresses to adark greasy texture and in severe cases turns black. Such cases usuallydie due to the toxins produced by the staphylococci organisms. Innurseries, up to 15% of the population may be involved and dehydrationis common.

Streptococcal meningitis causes inflammation of the meninges which arethe membranes covering the brain. In the sucking piglet, it is usuallycaused by bacteria of Streptococcus spp, e.g. Streptococcus suis,Haemophilus parasuis, or sometimes bacteria such as E. coli and otherstreptococci. S. suis has many serotypes. In most countries, S. suistype 1 is the main one in sucking piglets, but this may not be true inother countries. For example, in Denmark it is type 7. S. suis alsocauses joint problems particularly types 1 and 14. S. suis is carriedfor long periods in the tonsils and may be transmitted to the suckingpiglet from the sow or from other piglets. The sow also provides avariable level of immunity in the colostrum. Streptococcal meningitis insucking piglets is sporadic in individual piglets. Streptococcalmeningitis may be worse in sucking pigs when the organism has beenintroduced into the herd for the first time, or where it is secondary toinfection with PRRS.

Aujeszky's disease, or AD, is an important disease of pigs caused byswine herpes virus. The virus can remain hidden in nerves of the pig ina carrier state for long periods of time and then be reactivated. Onceintroduced into a herd the virus usually remains there and it cancontinually affect reproductive performance at varying levels. The viruscan survive for up to three weeks outside the pig. Acute outbreaks ofdisease occur when virulent strains of the virus first infect anunvaccinated susceptible herd. The virus crosses the uterus and placentaand infects the fetuses. The pig is the main host. However, dogs andcattle may also become infected, show nervous signs, and die.

Swine Influenza Virus causes swine flu and belongs to the influenza TypeA virus group. In naïve herds, clinical signs may present in explosiveoutbreaks with all or many animals becoming ill at the same time.Animals may present with inactivity, depression, huddling/pilling andanorexia. The animals are often mouth-breathing and breathing islabored. Coughing may ensue upon movement. Other clinical signs includea nasal discharge and puffy eyes with rectal temperatures between40.5-41.5° Celsius. The high temperatures in a breeding stock can resultin abortions, infertility, production of small weak litters, andincreased still births. In established herds, annual reinfectionappears.

Swine Pox is a disease which causes skin lesions, paules, pustules andscabs. It is caused by Swine pox virus.

Swine Vesicular Disease (SVD) is a different virus from the virus thatcauses foot and mouth disease (FMD). However, it produces a disease inpigs that is clinically indistinguishable from FMD. This disease shouldalways be considered if sudden widespread lameness appears with vesiclesor blisters on the snout, tongue and tops of the claws.

Transmissible gastroenteritis (TGE) is a disease of the intestinescaused by a coronavirus (Transmissible gastroenteritis virus). It is inthe same family as Porcine respiratory coronavirus, epidemic diarrheavirus, and Hemagglutinating encephalomyelitis virus. Initial clinicalsigns are watery diarrhea, vomiting, and anorexia. Piglets less than 21days of age generally die, weaners become unthrifty, while growers,finishers, and adults are generally mildly affected and will survive ifprovided with adequate water.

DESCRIPTION OF THE INVENTION

The present invention provides combination vaccines which comprise i) animmunological agent effective for reducing the incidence of or lesseningthe severity of PPE caused by L. intracellularis, and ii) one or moreimmunological active components effective in treatment and/orprophylaxis of at least one further disease-causing organism for swine.In particular, the immunological agent effective for reducing theincidence of or lessening the severity of PPE is L. intracellularis.

As used herein, the term “L. intracellularis” means the intracellular,curved gram-negative bacteria described in detail by C. Gebhart et al.,Int'l. J. of Systemic Bacteriology, Vol. 43, No. 3, 533-538 (1993) andS. McOrist et al., Int'l. J. of Systemic Bacteriology, Vol. 45, No. 4,820-825 (1995), each of which is incorporated herein by reference intheir entireties, and includes but is not limited to the isolatesdescribed in WO 96/39629 and WO 05/011731. In particular, the term “L.intracellularis” also means, but is not limited to the isolatesdeposited under the Budapest Treaty with the American Type CultureCollection, 10801 University Boulevard, Manassas, Va. 20110-2209 andassigned ATCC accession number PTA 4926 or ATCC accession number 55783.Both isolates are described in WO 96/39629 and WO 05/011731,respectively. The term “L. intracellularis” also means, but is notlimited to any other L. intracellularis bacteria strain or isolatepreferably having the immunogenic properties of at least one of the L.intracellularis strains described in WO 96/39629 and WO 05/011731, inparticular having the immunogenic properties of at least one of theisolates deposited under the Budapest Treaty with the American TypeCulture Collection, 10801 University Boulevard, Manassas, Va. 20110-2209and assigned ATCC accession numbers PTA 4926 or ATCC accession number55783.

A strain or isolate has the “immunogenic properties” of at least one ofthe L. intracellularis strains described in WO 96/39629 and WO05/011731, in particular, of the isolates deposited as ATCC accessionnumber PTA 4926 or ATCC accession number 55783, when it is detectable atleast with one of the anti-L. intracellularis specific antibodies,described in WO06/01294, in a detection assay that is also described inWO06/01294. Preferably those antibodies are selected from the antibodieshaving the reference numbers 301:39, 287:6, 268:29, 110:9, 113:2 and268:18. Preferably, the detection assay is a sandwich ELISA as describedin Examples 2 and 3 of WO06/12949, whereas antibody 110:9 is used as acapture antibody and antibody 268:29 is used as conjugated antibody. Allantibodies disclosed in WO06/12949 are produced by hybridoma cells,which are deposited at the Centre for Applied Microbiology and Research(CAMR) and European Collection of Cell Cultures (ECACC)”, Salisbury,Wiltshire SP4 0JG, UK, as a patent deposit according to the BudapestTreaty. The date of deposit was May 11, 2004. HYBRIDOMA CELL LINE 110:9is successfully deposited under ECACC Acc. No. 04092204. HYBRIDOMA CELLLINE 113:2 is successfully deposited under ECACC Acc. No. 04092201.HYBRIDOMA CELL LINE 268:18 is successfully deposited under ECACC Acc.No. 04092202. HYBRIDOMA CELL LINE 268:29 is successfully deposited underECACC Acc. No. 04092206. HYBRIDOMA CELL LINE 287:6 is successfullydeposited under ECACC Acc. No. 04092203. HYBRIDOMA CELL LINE 301:39 issuccessfully deposited under ECACC Acc. No. 04092205.

Moreover, the term “L intracellularis” also means any L. intracellularisantigen. The term “L. intracellularis antigen” as used herein means, butis not limited to any composition of matter, that comprises at least oneantigen that can induce, stimulate or enhance the immune responseagainst a L. intracellularis-caused infection, when administered to apig. Preferably, said L. intracellularis antigen is a complete L.intracellularis bacterium, in particular in an inactivated form (a socalled killed bacterium), a modified live or attenuated L.intracellularis bacterium (a so called MLB), a chimeric vector thatcomprises at least an immunogenic amino acid sequence of L.intracellularis, or any other polypeptide or component, that comprisesat least an immunogenic amino acid sequence of L. intracellularis. Theterms “immunogenic protein”, “immunogenic polypeptide” or “immunogenicamino acid sequence” as used herein refer to any amino acid sequencewhich elicits an immune response in a host against a pathogen comprisingsaid immunogenic protein, immunogenic polypeptide or immunogenic aminoacid sequence. In particular, an “immunogenic protein”, “immunogenicpolypeptide” or “immunogenic amino acid sequence” of L. intracellularismeans any amino acid sequence that codes for an antigen which elicits animmunological response against L. intracellularis in a host to whichsaid “immunogenic protein”, “immunogenic polypeptide” or “immunogenicamino acid sequence” is administered.

An “immunogenic protein”, “immunogenic polypeptide” or “immunogenicamino acid sequence” as used herein, includes but is not limited to thefull-length sequence of any proteins, analogs thereof, or immunogenicfragments thereof. The term “immunogenic fragment” means a fragment of aprotein which includes one or more epitopes and thus elicits theimmunological response against the relevant pathogen. Such fragments canbe identified using any number of epitope mapping techniques that arewell known in the art. See, e.g., Epitope Mapping Protocols in Methodsin Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press,Totowa, N.J. (The teachings and content of which are incorporated byreference herein.) For example, linear epitopes may be determined bye.g., concurrently synthesizing large numbers of peptides on solidsupports, the peptides corresponding to portions of the proteinmolecule, and reacting the peptides with antibodies while the peptidesare still attached to the supports. Such techniques are known in the artand described in, e.g., U.S. Pat. No. 4,708,871; Geysen et al. (1984)Proc. Natl. Acad. Sci. USA 81:3998-4002; Geysen et al. (1986) Molec.Immunol. 23:709-715. (The teachings and content of which areincorporated by reference herein.) Similarly, conformational epitopesare readily identified by determining spatial conformation of aminoacids such as by, e.g., x-ray crystallography and 2-dimensional nuclearmagnetic resonance. See, e.g., Epitope Mapping Protocols, supra.Synthetic antigens are also included within the definition, for example,polyepitopes, flanking epitopes, and other recombinant or syntheticallyderived antigens. See, e.g., Bergmann et al. (1993) Eur. J. Immunol.23:2777-2781; Bergmann et al. (1996), J. Immunol. 157:3242-3249;Suhrbier, A. (1997), Immunol. and Cell Biol. 75:402-408; Gardner et al.,(1998) 12th World AIDS Conference, Geneva, Switzerland, Jun. 28-Jul. 3,1998. (The teachings and content of which are incorporated by referenceherein.)

An “immunological or immune response” to a composition or vaccine is thedevelopment in the host of a cellular and/or antibody-mediated immuneresponse to the composition or vaccine of interest. Usually, an “immuneresponse” includes but is not limited to one or more of the followingeffects: the production or activation of antibodies, B cells, helper Tcells, suppressor T cells, and/or cytotoxic T cells and/or yd T cells,directed specifically to an antigen or antigens included in thecomposition or vaccine of interest. Preferably, the host will displayeither a therapeutic or protective immunological response such thatresistance to new infection will be enhanced and/or the clinicalseverity of the disease reduced. Such protection will be demonstrated byeither a reduction or lack of the symptoms associated with hostinfections as described above.

Suitable L. intracellularis antigens include, but are not limited tothose described in EP 1219711; U.S. Pat. No. 6,605,696; WO 96/39629;WO97/20050; WO 00/69903; WO 00/69904; WO 00/69905; WO 00/69906; WO02/38594; WO 02/26250; WO 03/006665; WO 04/033631; WO 05/026200; WO05/011731.

As described above, the present invention relates to combinationvaccines which comprise i) an immunological agent effective for reducingthe incidence of or lessening the severity of PPE caused by L.intracellularis, and ii) one or more immunological active componentseffective in the treatment and/or prophylaxis of at least one furtherdisease-causing organism for swine. Preferably the furtherdisease-causing organism for swine is selected from the group consistingof: enteric pathogens which include Salmonella spp. (1), in particularS. typhimurium (1a), S. choleraesuis (1b); Astroviruses (2); Rotavirus(3); Transmissible gastroenteritis virus (4); Brachyspira spp (5), inparticular B. hyodysenteriae (5a), B. pilosicoli (5b); Clostridium spp.(6), in particular C. difficile (6a), C. perfringens types A, B and C(6b), C. novyi (6c), C. septicum (6d), C. tetani (6e); Porcine entericpicornaviruses (7); Porcine enteric caliciviruses (8); respiratorypathogens, which include: Actinobacillus pleuropneumonia (9); Bordetellabronchiseptica (10); Erysipelothrix rhsiopathiae (11); Haemophilusparasuis (12), in particular subtypes 1, 7 and 14; Pasteurella spp.(13), in particular P. multocida (13a); Mycoplasma spp. (14), inparticular M. hyopneumoniae (14a), M. hyorhinis (14b); Swine influenzavirus (15); PRRS virus (16); Porcine circovirus (17); Porcine parvovirus(18); Pseudorabies virus (19); Eperythrozoonosis suis (20) Mycobacteriumspp. (21), in particular M. avium (21a), M. intracellulare (21b), M.bovis (21c); Porcine respiratory corona virus (22); Arcanobacteriumpyogenes (23); Porcine adenovirus (24); Clasical swine fever (25);Porcine cytomegalovirus (26); African swine fever (27); or otherpathogens, which include Escherichia coli (28), Streptococcus spp. (29),in particular S. suis (29a), S. porcinus (29b), S. dysgalactiae (29c),preferably subsp. equisimilis (29c1); Brucella suis (30), in particularbiovars 1, 2 and 3; Leptospira spp. (31), in particular L.australis(31a), L. canicola (31b), L. grippotyphosa (31c), L. pomona(31d), L. icterohaemorrhagicae (31e), L. interrogans (31f), L. tarassovi(31g), L. hardjo (31h), L. sejroe (31i); Encephalomyocarditis virus(32); Hemagglutinating encephalomyelitis virus (33); Japaneseencephalitis virus (34); West Nile virus (35); Reovirus (36);Rubulavirus (37); Menangle virus (38); Nipah virus (39); Vesicularstomatitis virus (40); Virus of vesicular exanthema of swine (41); Swinepox virus (42); Swine herpes virus (43); and Staphylococcus hyicus (44).

Any reference made in the following to one or more of the swinepathogens listed-above is made either by naming the pathogen, forexample M. hyopneumoniae, or by making reference to the number that isput in parentheses behind the pathogen, e.g. (M. hyopneumoniae=(14a)).

Thus, the present invention relates to a combination vaccine for thetreatment and/or prophylaxis of swine, that comprises i) animmunological agent effective for reducing the incidence of or lesseningthe severity of an L. intracellularis infection, preferably a L.intracellularis antigen, and ii) one or more immunological activecomponent(s) effective for the treatment and/or prophylaxis ofinfections caused by one or more of the swine pathogens selected fromthe group consisting of: (1), (1a), (1b), (2), (3), (4), (5), (5a),(5b), (6), (6a), (6b), (6c), (6d), (6e), (7), (8), (9), (10), (11),(12), (13), (13a), (14), (14a), (14b), (15), (16), (17), (18), (19),(20), (21), (21a), (21b), (21c), (22), (23), (24), (25), (26), (27),(28), (29), (29a), (29b), (29c), (29c1), (30), (31) (31a), (31b), (31c),(31d), (31e), (31f), (31g), (31h), (31i), (32), (33), (34), (35), (36),(37), (38), (39), (40), (41), (42), (43) and (44). Preferably theimmunological active component of said combination vaccine comprises orconsists of one or more modified live microorganisms, one or morekilled-microorganisms, or one or more immunological active part(s) ofone or more microorganisms selected from the group consisting of (1),(1a), (1b), (2), (3), (4), (5), (5a), (5b), (6), (6a), (6b), (6c), (6d),(6e), (7), (8), (9), (10), (11), (12), (13), (13a), (14), (14a), (14b),(15), (16), (17), (18), (19), (20), (21), (21a), (21b), (21c), (22),(23), (24), (25), (26), (27), (28), (28), (29), (29a), (29b), (29c),(29c1), (30), (31) (31a), (31b), (31c), (31d), (31e), (31f), (31g),(31h), (31i), (32), (33), (34), (35), (36), (37), (38), (39), (40),(41), (42), (43) and (44). [combo 1].

An “immunological active component” as used herein means a componentthat induces or stimulates the immune response in an animal to whichsaid component is administered. Preferably, the immune response isdirected to said component or to an microorganism comprising saidcomponent. According to a further preferred embodiment, theimmunological active component is an attenuated microorganism, includingbut not limited to a modified live virus or bacterium (MLV or MLB), akilled-microorganism or at least an immunological active part of amicroorganism.

“Immunological active part of a microorganism” as used herein means aprotein-, sugar-, and or glycoprotein containing fraction of amicroorganism that comprises at least one antigen that induces orstimulates the immune response in an animal to which said component isadministered. According to a preferred embodiment, said immune responseis directed to said immunological active part of the microorganism or tothe microorganism that comprises said immunological active part.

Preferably the immunological active component of [combo 1] is effectivefor the treatment and/or prophylaxis of infections caused by the swinepathogen (11) [combo 2], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogen (11) [combo 3].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogen (9) [combo 4], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (9) [combo5].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogen (10) [combo 6], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (10) [combo7].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogen (12) [combo 8], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (12) [combo9].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogen (13), in particular (13a) [combo10], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogen (13), in particular (13a) [combo 11].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogen (14), in particular (14a) and/or(14b) [combo 12], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogen (14), in particular (14a) and/or(14b)[combo 13].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogen (15) [combo 14], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (15) [combo15].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogen (16) [combo 16], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (16) [combo17].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogen (17) [combo 18], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (17) [combo19].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogen (18) [combo 20], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (18) [combo21].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogen (19) [combo 22], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (19) [combo23].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogen (29), in particular (29a) [combo24], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogen (29), in particular (29a) [combo 25].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); and (9) [combo 26], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogen (9) [combo 27].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); and (10) [combo 28], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); and (10) [combo 29].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); and (11) [combo 30], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); and (11) [combo 31].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); and (12) [combo 32], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); and (12) [combo 33].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); and (13), in particular (13a) [combo 34], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); and (13), in particular (13a) [combo 35].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); and (14), in particular (14a) and/or (14b) [combo 36], preferablysaid immunological active component comprises a live modified form, akilled form, or an immunological active part of said swine pathogens(1), in particular (1a) and/or (1b); and (14), in particular (14a)and/or (14b)[combo 37].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); and (15) [combo 38], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); and (15) [combo 39].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); and (16) [combo 40], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); and (16) [combo 41].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); and (17) [combo 42], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); and (17) [combo 43].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); and (18) [combo 44], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); and (18) [combo 45].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); and (19) [combo 46], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); and (19) [combo 47].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); and (29), in particular (29a) [combo 48], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); and (29), in particular (29a) [combo 49].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); and (10) [combo 50],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (9); and (10) [combo 51].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); and (11) [combo 52],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (9); and (11) [combo 53]. According to a more preferredembodiment, the immunological active component of [combo 1] isENTERISOL®SC-54 (Salmonella choleraesius, Boehringer Ingelheim VetmedicaInc., St. Joseph, Mo., U.S.) and INGELVAC® ERY-ALC (Erysipelothrixrhusiopathiae, Boehringer Ingelheim Vetmedica Inc., St. Joseph, Mo.,U.S.) [combo 54]. According to a further embodiment, the L.intracellularis antigen of combo 54 is ENTERISOL® Ileitis FF (BoehringerIngelheim Vetmedica Inc., St. Joseph, Mo., U.S.) [combo 55] orENTERISOL® Ileitis Lyophilized (Boehringer Ingelheim Vetmedica GmbH,Ingelheim am Rhein, Germany) [combo 56].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); and (12) [combo 57],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (9); and (12) [combo 58].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); and (13), in particular(13a) [combo 59], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (9); and (13), in particular (13a)[combo 60].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); and (14), in particular(14a) and/or (14b) [combo 61], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); and (14), inparticular (14a) and/or (14b)[combo 62].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); and (15) [combo 63],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (9); and (15) [combo 64].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); and (16) [combo 65],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (9); and (16) [combo 66].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); and (17) [combo 67],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (9); and (17) [combo 68].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); and (18) [combo 69],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (9); and (18) [combo 70].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); and (19) [combo 71],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (9); and (19) [combo 72].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); and (29), in particular(29a) [combo 73], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (9); and (29), in particular (29a)[combo 74].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (10); and (11) [combo 75],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (10); and (11) [combo 76].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (10); and (12) [combo 77],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (10); and (12) [combo 78].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (10); and (13), in particular(13a) [combo 79], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (10); and (13), in particular (13a)[combo 80].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (10); and (14), in particular(14a) and/or (14b) [combo 81], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (10); and (14), inparticular (14a) and/or (14b)[combo 82].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (10); and (15) [combo 83],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (10); and (15) [combo 84].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (10); and (16) [combo 85],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (10); and (16) [combo 86].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (10); and (17) [combo 87],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (10); and (17) [combo 88].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (10); and (18) [combo 89],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (10); and (18) [combo 90].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (10); and (19) [combo 91],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (10); and (19) [combo 92].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (10); and (29), in particular(29a) [combo 93], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (10); and (29), in particular (29a)[combo 94].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); and (12) [combo 95],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (11); and (12) [combo 96].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); and (13), in particular(13a) [combo 97], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (11); and (13), in particular (13a)[combo 98].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); and (14), in particular(14a) and/or (14b) [combo 99], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); and (14), inparticular (14a) and/or (14b)[combo 100].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); and (15) [combo 101],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (11); and (15) [combo 102].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); and (16) [combo 103],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (11); and (16) [combo 104].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); and (17) [combo 105],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (11); and (17) [combo 106].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); and (18) [combo 107],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (11); and (18) [combo 108].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); and (19) [combo 109],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (11); and (19) [combo 110].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); and (29), in particular(29a) [combo 111], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (11); and (29), in particular (29a)[combo 112].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); and (13), in particular(13a) [combo 113], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (12); and (13), in particular (13a)[combo 114].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); and (14), in particular(14a) and/or (14b) [combo 115], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); and (14), inparticular (14a) and/or (14b)[combo 116].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); and (15) [combo 117],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (12); and (15) [combo 118].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); and (16) [combo 119],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (12); and (16) [combo 120].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); and (17) [combo 121],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (12); and (17) [combo 122].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); and (18) [combo 123],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (12); and (18) [combo 124].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); and (19) [combo 125],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (12); and (19) [combo 126].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); and (29), in particular(29a) [combo 127], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (12); and (29), in particular (29a)[combo 128].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a); and(14), in particular (14a) and/or (14b) [combo 129], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (13), inparticular (13a); and (14), in particular (14a) and/or (14b)[combo 130].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a); and(15) [combo 131], preferably said immunologic al active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (13), in particular (13a); and (15)[combo 132].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a); and(16) [combo 133], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (13), in particular (13a); and (16)[combo 134].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a); and(17) [combo 135], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (13), in particular (13a); and (17)[combo 136].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a); and(18) [combo 137], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (13), in particular (13a); and (18)[combo 138].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a); and(19) [combo 139], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (13), in particular (13a); and (19)[combo 140].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a); and(29), in particular (29a) [combo 141], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); and (29), in particular (29a) [combo 142].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a); and(15) [combo 143], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (14), in particular (14a); and (15)[combo 144].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a); and(16) [combo 145], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (14), in particular (14a); and (16)[combo 146].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a); and(17) [combo 147], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (14), in particular (14a); and (17)[combo 148].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a); and(18) [combo 149], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (14), in particular (14a); and (18)[combo 150].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a); and(19) [combo 151], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (14), in particular (14a); and (19)[combo 152].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a); and(29), in particular (29a) [combo 153], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a); and (29), in particular (29a) [combo 154].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (15); and (16) [combo 155],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (15); and (16) [combo 156].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (15); and (17) [combo 157],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (15); and (17) [combo 158].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (15); and (18) [combo 159],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (15); and (18) [combo 160].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (15); and (19) [combo 161],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (15); and (19) [combo 162].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (15); and (29), in particular(29a) [combo 163], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (15); and (29), in particular (29a)[combo 164].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); and (17) [combo 165],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (16); and (17) [combo 166].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); and (18) [combo 167],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (16); and (18) [combo 168].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); and (19) [combo 169],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (16); and (19) [combo 170].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); and (29), in particular(29a) [combo 171], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (16); and (29), in particular (29a)[combo 172].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (17); and (18) [combo 173],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (17); and (18) [combo 174].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (17); and (19) [combo 175],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (17); and (19) [combo 176].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (17); and (29), in particular(29a) [combo 177], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (17); and (29), in particular (29a)[combo 178].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (18); and (19) [combo 179],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (18); and (19) [combo 180].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (18); and (29), in particular(29a) [combo 181], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (18); and (29), in particular (29a)[combo 182].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (19); and (29), in particular(29a) [combo 183], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (19); and (29), in particular (29a)[combo 184].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (9); and (10) [combo 185], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (9); and (10) [combo 186].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (9); and (11) [combo 187], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (9); and (11) [combo 188].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (9); and (12) [combo 189], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (9); and (12) [combo 190].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (9); and (13), in particular (13a) [combo 191], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (9); and (13), in particular (13a) [combo192].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (9); and (14), in particular (14a) and/or (14b) [combo 193],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (1), in particular (1a) and/or (1b); (9); and (14), inparticular (14a) and/or (14b)[combo 194].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (9); and (15) [combo 195], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (9); and (15) [combo 196].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (9); and (16) [combo 197], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (9); and (16) [combo 198].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (9); and (17) [combo 199], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (9); and (17) [combo 200].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (9); and (18) [combo 201], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (9); and (18) [combo 202].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (9); and (19) [combo 203], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (9); and (19) [combo 204].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (9); and (29), in particular (29a) [combo 205], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (9); and (29), in particular (29a) [combo206].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (10); and (11) [combo 207], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (10); and (11) [combo 208].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (10); and (12) [combo 209], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (10); and (12) [combo 210].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (10); and (13), in particular (13a) [combo 211], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (10); and (13), in particular (13a) [combo212].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (10); and (14), in particular (14a) and/or (14b) [combo 213],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (1), in particular (1a) and/or (1b); (10); and (14), inparticular (14a) and/or (14b)[combo 214].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (10); and (15) [combo 215], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (10); and (15) [combo 216].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (10); and (16) [combo 217], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (10); and (16) [combo 218].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (10); and (17) [combo 219], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (10); and (17) [combo 220].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (10); and (18) [combo 221], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (10); and (18) [combo 222].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (10); and (19) [combo 223], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (10); and (19) [combo 224].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (10); and (29), in particular (29a) [combo 225], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (10); and (29), in particular (29a) [combo226].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (11); and (12) [combo 227], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (11); and (12) [combo 228].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (11); and (13), in particular (13a) [combo 229], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (11); and (13), in particular (13a) [combo230].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (11); and (14), in particular (14a) and/or (14b) [combo 231],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (1), in particular (1a) and/or (1b); (11); and (14), inparticular (14a) and/or (14b) [combo 232].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (11); and (15) [combo 233], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogen (1), in particular (1a)and/or (1b); (11); and (15) [combo 234].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (11); and (16) [combo 235], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (11); and (16) [combo 236].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (11); and (17) [combo 237], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (11); and (17) [combo 238].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (11); and (18) [combo 239], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (11); and (18) [combo 240].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (11); and (19) [combo 241], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (11); and (19) [combo 242].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (11); and (29), in particular (29a) [combo 243], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (11); and (29), in particular (29a) [combo244].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (12); and (13), in particular (13a) [combo 245], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (12); and (13), in particular (13a) [combo246].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (12); and (14), in particular (14a) and/or (14b) [combo 247],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (1), in particular (1a) and/or (1b); (12); and (14), inparticular (14a) and/or (14b)[combo 248].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (12); and (15) [combo 249], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogen (1), in particular (1a)and/or (1b); (12); and (15) [combo 250].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (12); and (16) [combo 251], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (12); and (16) [combo 252].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (12); and (17) [combo 253], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (12); and (17) [combo 254].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (12); and (18) [combo 255], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (12); and (18) [combo 256].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (12); and (19) [combo 257], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (12); and (19) [combo 258].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (12); and (29), in particular (29a) [combo 259], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (12); and (29), in particular (29a) [combo260].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (13), in particular (13a); and (14), in particular (14a) and/or(14b) [combo 261], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (1), in particular (1a) and/or (1b);(13), in particular (13a); and (14), in particular (14a) and/or(14b)[combo 262].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (13), in particular (13a); and (15) [combo 263], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (1), inparticular (1a) and/or (1b); (13), in particular (13a); and (15) [combo264].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (13), in particular (13a); and (16) [combo 265], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (13), in particular (13a); and (16) [combo266].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (13), in particular (13a); and (17) [combo 267], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (13), in particular (13a); and (17) [combo268].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (13), in particular (13a); and (18) [combo 269], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (13), in particular (13a); and (18) [combo270].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (13), in particular (13a); and (19) [combo 271], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (13), in particular (13a); and (19) [combo272].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (13), in particular (13a); and (29), in particular (29a) [combo273], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (1), in particular (1a) and/or (1b); (13), in particular(13a); and (29), in particular (29a) [combo 274].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (14), in particular (14a); and (15) [combo 275], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (1), inparticular (1a) and/or (1b); (14), in particular (14a); and (15) [combo276].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (14), in particular (14a); and (16) [combo 277], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (14), in particular (14a); and (16) [combo278].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (14), in particular (14a); and (17) [combo 279], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (14), in particular (14a); and (17) [combo280].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (14), in particular (14a); and (18) [combo 281], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (14), in particular (14a); and (18) [combo282].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (14), in particular (14a); and (19) [combo 283], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (14), in particular (14a); and (19) [combo284].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (14), in particular (14a); and (29), in particular (29a) [combo285], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (1), in particular (1a) and/or (1b); (14), in particular(14a); and (29), in particular (29a) [combo 286].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (15); and (16) [combo 287], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (15); and (16) [combo 288].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (15); and (17) [combo 289], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (15); and (17) [combo 290].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (15); and (18) [combo 291], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (15); and (18) [combo 292].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (15); and (19) [combo 293], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (15); and (19) [combo 294].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (15); and (29), in particular (29a) [combo 295], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (15); and (29), in particular (29a) [combo296].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (16); and (17) [combo 297], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (15); and (17) [combo 298].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (16); and (18) [combo 299], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (16); and (18) [combo 300].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (16); and (19) [combo 301], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (16); and (19) [combo 302].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (16); and (29), in particular (29a) [combo 303], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (16); and (29), in particular (29a) [combo304].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (17); and (18) [combo 305], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (17); and (18) [combo 306].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (17); and (19) [combo 307], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (17); and (19) [combo 308].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (17); and (29), in particular (29a) [combo 309], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (17); and (29), in particular (29a) [combo310].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (18); and (19) [combo 311], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (1), in particular(1a) and/or (1b); (18); and (19) [combo 312].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (18); and (29), in particular (29a) [combo 313], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (18); and (29), in particular (29a) [combo314].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (19); and (29), in particular (29a) [combo 315], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (1), inparticular (1a) and/or (1b); (19); and (29), in particular (29a) [combo316].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (10); and (11) [combo317], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (10); and (11) [combo 318].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (10); and (12) [combo319], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (10); and (12) [combo 320].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (10); and (13), inparticular (13a) [combo 321], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (10); and (13),in particular (13a) [combo 322].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (10); and (14), inparticular (14a) and/or (14b) [combo 323], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (10); and (14),in particular (14a) and/or (14b)[combo 324].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (10); and (15) [combo325], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (10); and (15) [combo 326].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (10); and (16) [combo327], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (10); and (16) [combo 328].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (10); and (17) [combo329], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (10); and (17) [combo 330].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (10); and (18) [combo331], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (10); and (18) [combo 332].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (10); and (19) [combo333], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (10); and (19) [combo 334].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (10); and (29), inparticular (29a) [combo 335], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (10); and (29),in particular (29a) [combo 336].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (11); and (12) [combo337], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (11); and (12) [combo 338].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (1), in particular (1a) and/or(1b); (11); and (13), in particular (13a) [combo 339], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (9); (11);and (13), in particular (13a) [combo 340].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (11); and (14), inparticular (14a) and/or (14b) [combo 341], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (11); and (14),in particular (14a) and/or (14b)[combo 342].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (11); and (15) [combo343], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogen (9); (11); and (15) [combo 344].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (11); and (16) [combo345], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (11); and (16) [combo 346].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (11); and (17) [combo347], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (11); and (17) [combo 348].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (11); and (18) [combo349], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (11); and (18) [combo 350].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (11); and (19) [combo351], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (11); and (19) [combo 352].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (11); and (29), inparticular (29a) [combo 353], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (11); and (29),in particular (29a) [combo 354].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (12); and (13), inparticular (13a) [combo 355], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (12); and (13),in particular (13a) [combo 356].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (12); and (14), inparticular (14a) and/or (14b) [combo 357], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (12); and (14),in particular (14a) and/or (14b)[combo 358].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (12); and (15) [combo359], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogen (9); (12); and (15) [combo 360].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (12); and (16) [combo361], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (12); and (16) [combo 362].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (12); and (17) [combo363], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (12); and (17) [combo 364].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (12); and (18) [combo365], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (12); and (18) [combo 366].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (12); and (19) [combo367], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (12); and (19) [combo 368].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (12); and (29), inparticular (29a) [combo 369], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (12); and (29),in particular (29a) [combo 370].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (13), in particular (13a);and (14), in particular (14a) and/or (14b) [combo 371], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (9); (13),in particular (13a); and (14), in particular (14a) and/or (14b)[combo372].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9), (13), in particular (13a);and (15) [combo 373], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogen (9); (13), in particular (13a); and(15) [combo 374].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (13), in particular (13a);and (16) [combo 375], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (9); (13), in particular (13a); and(16) [combo 376].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (13), in particular (13a);and (17) [combo 377], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (9); (13), in particular (13a); and(17) [combo 378].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (13), in particular (13a);and (18) [combo 379], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (9); (13), in particular (13a); and(18) [combo 380].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (13), in particular (13a);and (19) [combo 381], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (9); (13), in particular (13a); and(19) [combo 382].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (13), in particular (13a);and (29), in particular (29a) [combo 383], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9), in particular(13a); and (29), in particular (29a) [combo 384].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (14), in particular (14a);and (15) [combo 385], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogen (9); (14), in particular (14a); and(15) [combo 386].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (14), in particular (14a);and (16) [combo 387], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (9); (14), in particular (14a); and(16) [combo 388].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (14), in particular (14a);and (17) [combo 389], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (9); (14), in particular (14a); and(17) [combo 390].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (14), in particular (14a);and (18) [combo 391], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (9); (14), in particular (14a); and(18) [combo 392].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (14), in particular (14a);and (19) [combo 393], preferably said immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogens (9); (14), in particular (14a); and(19) [combo 394].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (14), in particular (14a);and (29), in particular (29a) [combo 395], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (14), inparticular (14a); and (29), in particular (29a) [combo 396].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (15); and (16) [combo397], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (15); and (16) [combo 398].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (15); and (17) [combo399], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (15); and (17) [combo 400].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (15); and (18) [combo401], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (15); and (18) [combo 402].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (15); and (19) [combo403], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (15); and (19) [combo 404].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (15); and (29), inparticular (29a) [combo 405], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (15); and (29),in particular (29a) [combo 406].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (16); and (17) [combo407], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (15); and (17) [combo 408].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (16); and (18) [combo409], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (16); and (18) [combo 410].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (16); and (19) [combo411], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (16); and (19) [combo 412].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (16); and (29), inparticular (29a) [combo 413], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (16); and (29),in particular (29a) [combo 412].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (17); and (18) [combo413], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (17); and (18) [combo 414].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (17); and (19) [combo415], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (17); and (19) [combo 416].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (17); and (29), inparticular (29a) [combo 417], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (17); and (29),in particular (29a) [combo 418].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (18); and (19) [combo419], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (9); (18); and (19) [combo 420].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (18); and (29), inparticular (29a) [combo 421], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (18); and (29),in particular (29a) [combo 422].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9); (19); and (29), inparticular (29a) [combo 423], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (9); (19); and (29),in particular (29a) [combo 424].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (10); and (12) [combo425], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (10); and (12) [combo 426].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (10); and (13), inparticular (13a) [combo 427], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (10); and (13),in particular (13a) [combo 428].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (10); and (14), inparticular (14a) and/or (14b) [combo 429], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (10); and (14),in particular (14a) and/or (14b)[combo 430].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (10); and (15) [combo431], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (10); and (15) [combo 432].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (10); and (16) [combo433], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (10); and (16) [combo 434].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (10); and (17) [combo435], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (10); and (17) [combo 436].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (10); and (18) [combo437], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (10); and (18) [combo 438].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (10); and (19) [combo439], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (10); and (19) [combo 440].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (10); and (29), inparticular (29a) [combo 441], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (10); and (29),in particular (29a) [combo 442].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (12); and (13), inparticular (13a) [combo 443], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (12); and (13),in particular (13a) [combo 444].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (12); and (14), inparticular (14a) and/or (14b) [combo 445], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (12); and (14),in particular (14a) and/or (14b)[combo 446].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (12); and (15) [combo447], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogen (11); (12); and (15) [combo 448].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (12); and (16) [combo449], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (12); and (16) [combo 450].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (12); and (17) [combo451], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (12); and (17) [combo 452].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (12); and (18) [combo453], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (12); and (18) [combo 454].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (12); and (19) [combo455], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (12); and (19) [combo 456].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (12); and (29), inparticular (29a) [combo 457], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (12); and (29),in particular (29a) [combo 458].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (13), in particular(13a); and (14), in particular (14a) and/or (14b) [combo 459],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (11); (13), in particular (13a); and (14), in particular (14a)and/or (14b)[combo 460].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11), (13), in particular(13a); and (15) [combo 461], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogen (11); (13), inparticular (13a); and (15) [combo 462].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (13), in particular(13a); and (16) [combo 463], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (13), inparticular (13a); and (16) [combo 464].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (13), in particular(13a); and (17) [combo 465], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (13), inparticular (13a); and (17) [combo 466].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (13), in particular(13a); and (18) [combo 467], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (13), inparticular (13a); and (18) [combo 468].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (13), in particular(13a); and (19) [combo 469], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (13), inparticular (13a); and (19) [combo 470].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (13), in particular(13a); and (29), in particular (29a) [combo 471], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (11), inparticular (13a); and (29), in particular (29a) [combo 472].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (14), in particular(14a); and (15) [combo 473], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogen (11); (14), inparticular (14a); and (15) [combo 474].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (14), in particular(14a); and (16) [combo 475], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (14), inparticular (14a); and (16) [combo 476].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (14), in particular(14a); and (17) [combo 477], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (14), inparticular (14a); and (17) [combo 478].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (14), in particular(14a); and (18) [combo 479], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (14), inparticular (14a); and (18) [combo 480].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (14), in particular(14a); and (19) [combo 481], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (14), inparticular (14a); and (19) [combo 482].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (14), in particular(14a); and (29), in particular (29a) [combo 483], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (11);(14), in particular (14a); and (29), in particular (29a) [combo 484].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (15); and (16) [combo485], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (15); and (16) [combo 486].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (15); and (17) [combo487], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (15); and (17) [combo 488].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (15); and (18) [combo489], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (15); and (18) [combo 490].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (15); and (19) [combo491], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (15); and (19) [combo 492].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (15); and (29), inparticular (29a) [combo 493], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (15); and (29),in particular (29a) [combo 494].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (16); and (17) [combo495], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (15); and (17) [combo 496].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (16); and (18) [combo497], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (16); and (18) [combo 498].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (16); and (19) [combo499], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (16); and (19) [combo 500].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (16); and (29), inparticular (29a) [combo 501], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (16); and (29),in particular (29a) [combo 502].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (17); and (18) [combo503], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (17); and (18) [combo 504].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (17); and (19) [combo505], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (17); and (19) [combo 506].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (17); and (29), inparticular (29a) [combo 507], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (17); and (29),in particular (29a) [combo 508].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (18); and (19) [combo509], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (11); (18); and (19) [combo 510].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (18); and (29), inparticular (29a) [combo 511], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (18); and (29),in particular (29a) [combo 512].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (11); (19); and (29), inparticular (29a) [combo 513], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (11); (19); and (29),in particular (29a) [combo 514].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (10); and (13), inparticular (13a) [combo 515], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (10); and (13),in particular (13a) [combo 516].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (10); and (14), inparticular (14a) and/or (14b) [combo 517], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (10); and (14),in particular (14a) and/or (14b)[combo 518].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (10); and (15) [combo519], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (10); and (15) [combo 520].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (10); and (16) [combo521], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (10); and (16) [combo 522].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (10); and (17) [combo523], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (10); and (17) [combo 524].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (10); and (18) [combo525], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (10); and (18) [combo 526].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (10); and (19) [combo527], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (10); and (19) [combo 528].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (10); and (29), inparticular (29a) [combo 529], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (10); and (29),in particular (29a) [combo 530].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (13), in particular(13a); and (14), in particular (14a) and/or (14b) [combo 531],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (12); (13), in particular (13a); and (14), in particular (14a)and/or (14b)[combo 532].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12), (13), in particular(13a); and (15) [combo 533], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogen (12); (13), inparticular (13a); and (15) [combo 534].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (13), in particular(13a); and (16) [combo 535], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (13), inparticular (13a); and (16) [combo 536].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (13), in particular(13a); and (17) [combo 537], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (13), inparticular (13a); and (17) [combo 538].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (13), in particular(13a); and (18) [combo 539], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (13), inparticular (13a); and (18) [combo 540].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (13), in particular(13a); and (19) [combo 541], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (13), inparticular (13a); and (19) [combo 542].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (13), in particular(13a); and (29), in particular (29a) [combo 543], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (12), inparticular (13a); and (29), in particular (29a) [combo 544].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (14), in particular(14a); and (15) [combo 545], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogen (12); (14), inparticular (14a); and (15) [combo 546].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (14), in particular(14a); and (16) [combo 547], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (14), inparticular (14a); and (16) [combo 548].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (14), in particular(14a); and (17) [combo 549], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (14), inparticular (14a); and (17) [combo 550].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (14), in particular(14a); and (18) [combo 551], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (14), inparticular (14a); and (18) [combo 552].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (14), in particular(14a); and (19) [combo 553], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (14), inparticular (14a); and (19) [combo 554].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (14), in particular(14a); and (29), in particular (29a) [combo 555], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (12);(14), in particular (14a); and (29), in particular (29a) [combo 556].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (15); and (16) [combo557], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (15); and (16) [combo 558].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (15); and (17) [combo559], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (15); and (17) [combo 560].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (15); and (18) [combo561], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (15); and (18) [combo 562].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (15); and (19) [combo563], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (15); and (19) [combo 564].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (15); and (29), inparticular (29a) [combo 565], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (15); and (29),in particular (29a) [combo 566].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (16); and (17) [combo567], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (15); and (17) [combo 568].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (16); and (18) [combo569], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (16); and (18) [combo 570].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (16); and (19) [combo571], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (16); and (19) [combo 572].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (16); and (29), inparticular (29a) [combo 573], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (16); and (29),in particular (29a) [combo 574].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (17); and (18) [combo575], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (17); and (18) [combo 576].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (17); and (19) [combo577], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (17); and (19) [combo 578].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (17); and (29), inparticular (29a) [combo 579], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (17); and (29),in particular (29a) [combo 580].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (18); and (19) [combo581], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (12); (18); and (19) [combo 582].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (18); and (29), inparticular (29a) [combo 583], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (18); and (29),in particular (29a) [combo 584].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (12); (19); and (29), inparticular (29a) [combo 585], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (12); (19); and (29),in particular (29a) [combo 586].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(10); and (14), in particular (14a) and/or (14b) [combo 587], preferablysaid immunological active component comprises a live modified form, akilled form, or an immunological active part of said swine pathogens(13), in particular (13a); (10); and (14), in particular (14a) and/or(14b)[combo 588].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(10); and (15) [combo 589], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (10); and (15) [combo 590].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(10); and (16) [combo 591], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (10); and (16) [combo 592].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(10); and (17) [combo 593], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (10); and (17) [combo 594].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(10); and (18) [combo 595], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (10); and (18) [combo 596].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(10); and (19) [combo 597], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (10); and (19) [combo 598].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(10); and (29), in particular (29a) [combo 599], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (13), inparticular (13a); (10); and (29), in particular (29a) [combo 600].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(14), in particular (14a); and (15) [combo 601], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (13), inparticular (13a); (14), in particular (14a); and (15) [combo 602].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(14), in particular (14a); and (16) [combo 603], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (13), inparticular (13a); (14), in particular (14a); and (16) [combo 604].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(14), in particular (14a); and (17) [combo 605], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (13), inparticular (13a); (14), in particular (14a); and (17) [combo 606].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(14), in particular (14a); and (18) [combo 607], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (13), inparticular (13a); (14), in particular (14a); and (18) [combo 608].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(14), in particular (14a); and (19) [combo 609], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (13), inparticular (13a); (14), in particular (14a); and (19) [combo 610].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(14), in particular (14a); and (29), in particular (29a) [combo 611],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (13), in particular (13a); (14), in particular (14a); and(29), in particular (29a) [combo 612].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(15); and (16) [combo 613], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (15); and (16) [combo 614].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(15); and (17) [combo 615], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (15); and (17) [combo 616].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(15); and (18) [combo 617], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (15); and (18) [combo 618].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(15); and (19) [combo 619], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (15); and (19) [combo 620].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(15); and (29), in particular (29a) [combo 621], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (13), inparticular (13a); (15); and (29), in particular (29a) [combo 622].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(16); and (17) [combo 623], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (15); and (17) [combo 624].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(16); and (18) [combo 625], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (16); and (18) [combo 626].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(16); and (19) [combo 627], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (16); and (19) [combo 628].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(16); and (29), in particular (29a) [combo 629], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (13), inparticular (13a); (16); and (29), in particular (29a) [combo 630].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(17); and (18) [combo 631], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (17); and (18) [combo 632].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(17); and (19) [combo 633], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (17); and (19) [combo 634].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(17); and (29), in particular (29a) [combo 635], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (13), inparticular (13a); (17); and (29), in particular (29a) [combo 636].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(18); and (19) [combo 637], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (13), in particular(13a); (18); and (19) [combo 638].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(18); and (29), in particular (29a) [combo 639], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (13), inparticular (13a); (18); and (29), in particular (29a) [combo 640].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (13), in particular (13a);(19); and (29), in particular (29a) [combo 641], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (13), inparticular (13a); (19); and (29), in particular (29a) [combo 642].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (10); and (15) [combo 643], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (10); and (15) [combo 644].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (10); and (16) [combo 645], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (10); and (16) [combo 646].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (10); and (17) [combo 647], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (10); and (17) [combo 648].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (10); and (18) [combo 649], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (10); and (18) [combo 650].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (10); and (19) [combo 651], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (10); and (19) [combo 652].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (10); and (29), in particular (29a) [combo 653],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (14), in particular (14a) and/or (14b); (10); and (29), inparticular (29a) [combo 654].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (15); and (16) [combo 655], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (15); and (16) [combo 656].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (15); and (17) [combo 657], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (15); and (17) [combo 658].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (15); and (18) [combo 659], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (15); and (18) [combo 660].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (15); and (19) [combo 661], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (15); and (19) [combo 662].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (15); and (29), in particular (29a) [combo 663],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (14), in particular (14a) and/or (14b); (15); and (29), inparticular (29a) [combo 664].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (16); and (17) [combo 665], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (15); and (17) [combo 666].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (16); and (18) [combo 667], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (16); and (18) [combo 668].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (16); and (19) [combo 669], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (16); and (19) [combo 670].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (16); and (29), in particular (29a) [combo 671],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (14), in particular (14a) and/or (14b); (16); and (29), inparticular (29a) [combo 672].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (17); and (18) [combo 673], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (17); and (18) [combo 674].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (17); and (19) [combo 675], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (17); and (19) [combo 676].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (17); and (29), in particular (29a) [combo 677],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (14), in particular (14a) and/or (14b); (17); and (29), inparticular (29a) [combo 678].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (18); and (19) [combo 679], preferably said immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a) and/or (14b); (18); and (19) [combo 680].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (18); and (29), in particular (29a) [combo 681],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (14), in particular (14a) and/or (14b); (18); and (29), inparticular (29a) [combo 682].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a)and/or (14b); (19); and (29), in particular (29a) [combo 683],preferably said immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogens (14), in particular (14a) and/or (14b); (19); and (29), inparticular (29a) [combo 684].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (10); and (15) [combo685], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (16); (10); and (15) [combo 686].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (10); and (17) [combo687], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (16); (10); and (17) [combo 688].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (10); and (18) [combo689], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (16); (10); and (18) [combo 690].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (10); and (19) [combo691], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (16); (10); and (19) [combo 692].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (10); and (29), inparticular (29a) [combo 693], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (16); (10); and (29),in particular (29a) [combo 694].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (15); and (17) [combo695], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (16); (15); and (17) [combo 696].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (15); and (18) [combo697], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (16); (15); and (18) [combo 698].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (15); and (19) [combo699], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (16); (15); and (19) [combo 700].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (15); and (29), inparticular (29a) [combo 701], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (16); (15); and (29),in particular (29a) [combo 702].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (17); and (18) [combo703], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (16); (17); and (18) [combo 704].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (17); and (19) [combo705], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (16); (17); and (19) [combo 706].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (17); and (29), inparticular (29a) [combo 707], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (16); (17); and (29),in particular (29a) [combo 708].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (18); and (19) [combo709], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (16); (18); and (19) [combo 710].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (18); and (29), inparticular (29a) [combo 711], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (16); (18); and (29),in particular (29a) [combo 712].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (16); (19); and (29), inparticular (29a) [combo 713], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (16); (19); and (29),in particular (29a) [combo 714].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a),(16); (17); and (11) [combo 715], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a), (16); (17); and (11) [combo 716].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a),(16); (17); and (9) [combo 717], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a), (16); (17); and (9) [combo 718].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a),(16); (17); and (10) [combo 719], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a), (16); (17); and (10) [combo 720].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a),(16); (17); and (12) [combo 721], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a), (16); (17); and (12) [combo 722].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogen (13), in particular (13a) [combo723], preferably said immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogens (14), in particular (14a), (16); (17); and (13), inparticular (13a) [combo 724].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a),(16); (17); and (15) [combo 725], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a), (16); (17); and (15) [combo 726].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a),(16); (17); and (18) [combo 727], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a), (16); (17); and (18) [combo 728].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a),(16); (17); and (19) [combo 729], preferably said immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogens (14), in particular(14a), (16); (17); and (19) [combo 730].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (14), in particular (14a),(16); (17); and (29), in particular (29a) [combo 731], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (14), inparticular (14a), (16); (17); and (29), in particular (29a) [combo 732].

According to a further embodiment the immunological active component of[combo 1] is effective for the treatment and/or prophylaxis ofinfections caused by the swine pathogens (9), (11); (12); (14), inparticular (14a); (16); and (17) [combo 733], preferably saidimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (9); (11);(12); (14), in particular (14a), (16); and (17) [combo 734].

According to a further embodiment, the present invention relates to acombination vaccine according to [combo 733 or 734], that furthercomprises an immunological active component effective for the treatmentand/or prophylaxis of infections caused by infections caused by swinepathogen (13), in particular (13a); [combo 735], or preferably, whereinsaid further immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogen (13), in particular (13a) [combo 736].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 733, 734, 735 or736], that further comprises an immunological active component effectivefor the treatment and/or prophylaxis of infections caused by infectionscaused by swine pathogen (10) [combo 737], or preferably, wherein saidfurther immunological active component comprises a live modified form, akilled form, or an immunological active part of said swine pathogen(10), [combo 738].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 733, 734, 735, 736,737 or 738], that further comprises an immunological active componenteffective for the treatment and/or prophylaxis of infections caused byinfections caused by swine pathogen (1), in particular (1a) and/or (1b)[combo 739], or preferably, wherein said further immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogen (1), in particular (1a)and/or (1b) [combo 740].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 733, 734, 735, 736,737, 738, 739 or 740], that further comprises an immunological activecomponent effective for the treatment and/or prophylaxis of infectionscaused by infections caused by swine pathogen (29), in particular (29a)[combo 741], or preferably, wherein said further immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogen (29), in particular(29a) [combo 742].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 733, 734, 735, 736,737, 738, 739, 740, 741 or 742], that further comprises an immunologicalactive component effective for the treatment and/or prophylaxis ofinfections caused by infections caused by swine pathogen (15) [combo743], or preferably, wherein said further immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogen (15) [combo 744].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 733, 734, 735, 736,737, 738, 739, 740, 741, 742, 743 or 744], that further comprises animmunological active component effective for the treatment and/orprophylaxis of infections caused by infections caused by swine pathogen(18) [combo 745], or preferably, wherein said further immunologicalactive component comprises a live modified form, a killed form, or animmunological active part of said swine pathogen (18) [combo 746].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 733, 734, 735, 736,737, 738, 739, 740, 741, 742, 743, 744, 745 or 746], that furthercomprises an immunological active component effective for the treatmentand/or prophylaxis of infections caused by infections caused by swinepathogen (19) [combo 747], or preferably, wherein said furtherimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (19) [combo748].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 001, 002, 003, 004,005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018,019, 020, 021, 022, 023, 024, 025, 026, 027, 028, 029, 030, 031, 032,033, 034, 035, 036, 037, 038, 039, 040, 041, 042, 043, 044, 045, 046,047, 048, 049, 050, 051, 052, 053, 054, 055, 056, 057, 058, 059, 060,061, 062, 063, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074,075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088,089, 090, 091, 092, 093, 094, 095, 096, 097, 098, 099, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312,313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368,369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452,453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466,467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508,509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536,537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564,565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578,579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606,607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620,621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634,635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648,649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676,677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690,691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704,705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718,719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732,733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746,747 or 748], that further comprises an immunological active componenteffective for the treatment and/or prophylaxis of infections caused byinfections caused by swine pathogen (2) [combo 749], or preferably,wherein said further immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogen (2) [combo 750].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 001, 002, 003, 004,005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018,019, 020, 021, 022, 023, 024, 025, 026, 027, 028, 029, 030, 031, 032,033, 034, 035, 036, 037, 038, 039, 040, 041, 042, 043, 044, 045, 046,047, 048, 049, 050, 051, 052, 053, 054, 055, 056, 057, 058, 059, 060,061, 062, 063, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074,075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088,089, 090, 091, 092, 093, 094, 095, 096, 097, 098, 099, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312,313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368,369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452,453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466,467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508,509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536,537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564,565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578,579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606,607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620,621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634,635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648,649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676,677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690,691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704,705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718,719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732,733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746,747, 748, 749 or 750], that further comprises an immunological activecomponent effective for the treatment and/or prophylaxis of infectionscaused by infections caused by swine pathogen (3) [combo 751], orpreferably, wherein said further immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogen (3) [combo 752].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 001, 002, 003, 004,005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018,019, 020, 021, 022, 023, 024, 025, 026, 027, 028, 029, 030, 031, 032,033, 034, 035, 036, 037, 038, 039, 040, 041, 042, 043, 044, 045, 046,047, 048, 049, 050, 051, 052, 053, 054, 055, 056, 057, 058, 059, 060,061, 062, 063, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074,075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088,089, 090, 091, 092, 093, 094, 095, 096, 097, 098, 099, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312,313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368,369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452,453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466,467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508,509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536,537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564,565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578,579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606,607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620,621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634,635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648,649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676,677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690,691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704,705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718,719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732,733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746,747, 748, 749, 750, 751 or 752], that further comprises an immunologicalactive component effective for the treatment and/or prophylaxis ofinfections caused by infections caused by swine pathogen (4) [combo753], or preferably, wherein said further immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogen (4) [combo 754].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 001, 002, 003, 004,005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018,019, 020, 021, 022, 023, 024, 025, 026, 027, 028, 029, 030, 031, 032,033, 034, 035, 036, 037, 038, 039, 040, 041, 042, 043, 044, 045, 046,047, 048, 049, 050, 051, 052, 053, 054, 055, 056, 057, 058, 059, 060,061, 062, 063, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074,075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088,089, 090, 091, 092, 093, 094, 095, 096, 097, 098, 099, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312,313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368,369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452,453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466,467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508,509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536,537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564,565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578,579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606,607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620,621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634,635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648,649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676,677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690,691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704,705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718,719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732,733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746,747, 748, 749, 750, 751, 752, 753 or 754], that further comprises animmunological active component effective for the treatment and/orprophylaxis of infections caused by infections caused by swine pathogen(5), in particular (5a) and/or (5b) [combo 755], or preferably, whereinsaid further immunological active component comprises a live modifiedform, a killed form, or an immunological active part of said swinepathogen (5), in particular (5a) and/or (5b) [combo 756].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 001, 002, 003, 004,005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018,019, 020, 021, 022, 023, 024, 025, 026, 027, 028, 029, 030, 031, 032,033, 034, 035, 036, 037, 038, 039, 040, 041, 042, 043, 044, 045, 046,047, 048, 049, 050, 051, 052, 053, 054, 055, 056, 057, 058, 059, 060,061, 062, 063, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074,075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088,089, 090, 091, 092, 093, 094, 095, 096, 097, 098, 099, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312,313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368,369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452,453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466,467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508,509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536,537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564,565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578,579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606,607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620,621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634,635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648,649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676,677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690,691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704,705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718,719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732,733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746,747, 748, 749, 750, 751, 752, 753, 754, 755 or 756], that furthercomprises an immunological active component effective for the treatmentand/or prophylaxis of infections caused by infections caused by swinepathogen (6), in particular (6a), (6b), (6c), (6d) and/or (6e) [combo757], or preferably, wherein said further immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogen (6), in particular (6a), (6b), (6c),(6d) and/or (6e) [combo 758].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 001, 002, 003, 004,005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018,019, 020, 021, 022, 023, 024, 025, 026, 027, 028, 029, 030, 031, 032,033, 034, 035, 036, 037, 038, 039, 040, 041, 042, 043, 044, 045, 046,047, 048, 049, 050, 051, 052, 053, 054, 055, 056, 057, 058, 059, 060,061, 062, 063, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074,075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088,089, 090, 091, 092, 093, 094, 095, 096, 097, 098, 099, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312,313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368,369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452,453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466,467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508,509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536,537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564,565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578,579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606,607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620,621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634,635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648,649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676,677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690,691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704,705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718,719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732,733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746,747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757 or 758], thatfurther comprises an immunological active component effective for thetreatment and/or prophylaxis of infections caused by infections causedby swine pathogen (20) [combo 759], or preferably, wherein said furtherimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (20) [combo760].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 001, 002, 003, 004,005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018,019, 020, 021, 022, 023, 024, 025, 026, 027, 028, 029, 030, 031, 032,033, 034, 035, 036, 037, 038, 039, 040, 041, 042, 043, 044, 045, 046,047, 048, 049, 050, 051, 052, 053, 054, 055, 056, 057, 058, 059, 060,061, 062, 063, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074,075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088,089, 090, 091, 092, 093, 094, 095, 096, 097, 098, 099, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312,313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368,369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452,453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466,467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508,509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536,537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564,565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578,579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606,607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620,621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634,635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648,649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676,677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690,691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704,705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718,719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732,733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746,747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759 or 760],that further comprises an immunological active component effective forthe treatment and/or prophylaxis of infections caused by infectionscaused by swine pathogen (21), in particular (21a), (21b) and/or (21c)[combo 761], or preferably, wherein said further immunological activecomponent comprises a live modified form, a killed form, or animmunological active part of said swine pathogen (21), in particular(21a), (21b) and/or (21c) [combo 762].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 001, 002, 003, 004,005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018,019, 020, 021, 022, 023, 024, 025, 026, 027, 028, 029, 030, 031, 032,033, 034, 035, 036, 037, 038, 039, 040, 041, 042, 043, 044, 045, 046,047, 048, 049, 050, 051, 052, 053, 054, 055, 056, 057, 058, 059, 060,061, 062, 063, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074,075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088,089, 090, 091, 092, 093, 094, 095, 096, 097, 098, 099, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312,313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368,369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452,453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466,467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508,509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536,537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564,565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578,579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606,607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620,621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634,635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648,649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676,677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690,691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704,705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718,719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732,733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746,747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760,761 or 762], that further comprises an immunological active componenteffective for the treatment and/or prophylaxis of infections caused byinfections caused by swine pathogen (22) [combo 763], or preferably,wherein said further immunological active component comprises a livemodified form, a killed form, or an immunological active part of saidswine pathogen (22) [combo 764].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 001, 002, 003, 004,005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018,019, 020, 021, 022, 023, 024, 025, 026, 027, 028, 029, 030, 031, 032,033, 034, 035, 036, 037, 038, 039, 040, 041, 042, 043, 044, 045, 046,047, 048, 049, 050, 051, 052, 053, 054, 055, 056, 057, 058, 059, 060,061, 062, 063, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074,075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088,089, 090, 091, 092, 093, 094, 095, 096, 097, 098, 099, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312,313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368,369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452,453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466,467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508,509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536,537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564,565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578,579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606,607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620,621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634,635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648,649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676,677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690,691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704,705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718,719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732,733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746,747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760,761, 762, 763 or 764], that further comprises an immunological activecomponent effective for the treatment and/or prophylaxis of infectionscaused by infections caused by swine pathogens (29b) and/or (29c), inparticular (29c1) [combo 765], or preferably, wherein said furtherimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogens (29b)and/or (29c), in particular (29c1) [combo 766].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 001, 002, 003, 004,005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018,019, 020, 021, 022, 023, 024, 025, 026, 027, 028, 029, 030, 031, 032,033, 034, 035, 036, 037, 038, 039, 040, 041, 042, 043, 044, 045, 046,047, 048, 049, 050, 051, 052, 053, 054, 055, 056, 057, 058, 059, 060,061, 062, 063, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074,075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088,089, 090, 091, 092, 093, 094, 095, 096, 097, 098, 099, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312,313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368,369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452,453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466,467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508,509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536,537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564,565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578,579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606,607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620,621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634,635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648,649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676,677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690,691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704,705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718,719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732,733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746,747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760,761, 762, 763, 764, 765 or 766], that further comprises an immunologicalactive component effective for the treatment and/or prophylaxis ofinfections caused by infections caused by swine pathogen (30) [combo767], or preferably, wherein said further immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogen (30) [combo 768].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 001, 002, 003, 004,005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018,019, 020, 021, 022, 023, 024, 025, 026, 027, 028, 029, 030, 031, 032,033, 034, 035, 036, 037, 038, 039, 040, 041, 042, 043, 044, 045, 046,047, 048, 049, 050, 051, 052, 053, 054, 055, 056, 057, 058, 059, 060,061, 062, 063, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074,075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088,089, 090, 091, 092, 093, 094, 095, 096, 097, 098, 099, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312,313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368,369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452,453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466,467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508,509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536,537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564,565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578,579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606,607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620,621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634,635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648,649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676,677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690,691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704,705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718,719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732,733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746,747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760,761, 762, 763, 764, 765, 766, 767 or 768], that further comprises animmunological active component effective for the treatment and/orprophylaxis of infections caused by infections caused by swine pathogen(31), in particular (31a), (31b), (31c), (31d), (31e), (31f), (31g),(31h) and/or (31i) [combo 769], or preferably, wherein said furtherimmunological active component comprises a live modified form, a killedform, or an immunological active part of said swine pathogen (31), inparticular (31a), (31b), (31c), (31d), (31e), (31f), (31g), (31h) and/or(31i) [combo 770].

According to a further embodiment, the present invention relates to acombination vaccine according to any one of [combo 001, 002, 003, 004,005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018,019, 020, 021, 022, 023, 024, 025, 026, 027, 028, 029, 030, 031, 032,033, 034, 035, 036, 037, 038, 039, 040, 041, 042, 043, 044, 045, 046,047, 048, 049, 050, 051, 052, 053, 054, 055, 056, 057, 058, 059, 060,061, 062, 063, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074,075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088,089, 090, 091, 092, 093, 094, 095, 096, 097, 098, 099, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200,201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270,271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312,313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368,369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452,453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466,467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494,495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508,509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536,537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550,551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564,565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578,579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606,607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620,621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634,635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648,649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676,677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690,691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704,705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718,719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732,733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746,747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760,761, 762, 763, 764, 765, 766, 767 768, 769 or 770], that furthercomprises an immunological active component effective for the treatmentand/or prophylaxis of infections caused by infections caused by swinepathogens (7), (8), (23), (24), (25), (26), (27), (28) (32), (33), (34),(35), (36), (37), (38), (39), (40), (41), (42), (43) and/or (44) [combo771], or preferably, wherein said further immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of said swine pathogen (7), (8), (23), (24), (25), (26),(27), (28) (32), (33), (34), (35), (36), (37), (38), (39), (40), (41),(42), (43) and/or (44) [combo 772].

In one further embodiment, the combination vaccine comprises L.intracellularis and at least one immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of one or more swine pathogens selected from the groupconsisting of: (1b); (11); (4); (6), in particular (6a), (6b), (6c),(6d) and/or (6e); and (44) [combo 773].

In another embodiment, the combination vaccine comprises L.intracellularis and at least one immunological active componentcomprises a live modified form, a killed form, or an immunologicalactive part of one or more swine pathogens selected from the groupconsisting of: Clostridium spp. (e.g., Clostridium tetani), equineinfluenza virus (EIV) (e.g., EIV-1, EIV-2), equine herpes virus (EHV)(e.g., EHV-1, EHV-2, EHV-3, EHV-4, EHV-5, EHV-6, EHV-7), alphavirus(e.g., eastern encephalitis virus, western encephalitis virus,Venezuelan encephalitis virus), or West Nile virus [combo 774].

According to further aspect, the L. intracellularis antigen can alsocombined with the antigen(s), or with the final vaccine formulationlisted below [combo 775]: ENTERISOL® SC-54; ENTERISOL® SC-54 FF;ENTERISOL® Coli 3Plus; ENTERISOL® Coli-Clost; INGELVAC® Aujeszky MLV;INGELVAC® APP ALC; INGELVAC® APP ALC; INGELVAC®AR4; INGELVAC®ERY-ALC;INGELVAC® Flu; HP-1INGELVAC® HP-1; INGELVAC®M. HYO; INGELVAC® PRRS ATP;INGELVAC®PRRS MLV; INGELVAC® PRRS KV; INGELVAC®PRV-G1; REPROCYC®PRRS-PLE; TETGUARD™; TOXIVAC®AD+E; TOXIVAC® PLUS PARASUIS (BoehringerIngelheim); Argus® SC/ST; E-BAC®; END-FLUENCE®; END-FLUENCE®2;MAGESTIC®7 with SPUR®; MYCO SILENCER® BPM; MYCO SILENCER® BPME; MYCOSILENCER® M; MYCO SILENCER® MEH; MYCO SILENCER® Once; PORCILIS® APP;PORCILIS® AR-T; PORCILIS® Begonia; PORCILIS® Glasser; PORCILIS® PRRS;PROSYSTEM® CE; PROSYSTEM® Pilimune; PROSYSTEM® RCE; PROSYSTEM® TGE;PROSYSTEM® TGE/Rota; PROSYSTEM® TREC; RHINOGEN® BPE; RHINOGEN® CTE 5000;SOW BAC® CE II; SOW BAC® E II; SOW BAC® TREC; STREP BAC® with IMUGEN®II; SUPER-TET® with HAVLOGEN (Intervet Inc.); BratiVac-6; ER BAC®PLUS/LEPTOFERM-5®; ER BAC PLUS; FARROWSURE® PLUS; FARROWSURE® PLUS B;FLUSURE™; FLUSURE™ RTU; FLUSURE™/ER BAC® PLUS; FLUSURE™/RESPISURE®;FLUSURE™/RESPISURE ONE®; FLUSURE™/RESPISURE® RTU;FLUSURE™/RESPISURE-ONE®/ER BAC® PLUS; LITTERGUARD®; LITTERGUARD® LT;LITTERGUARD® LT-C; PARVO-VAC®/LEPTOFERM-5®; RESPISURE®; RESPISURE/ER®BAC PLUS®; RESPISURE-ONE®; RESPISURE-ONE/ER BAC PLUS (Pfizer Inc.);HYORESP®; NEOCOLIPOR® PROGRESSIS® (Merial LTD); M+PAC®, MAXIVAC® XL3, SSPac®, PNEU PAC®, PARAPAC®; PNEU PAC® −ER; AR-PARAPAC®+ER; PNEUPARAPAC®+ER; AR-Pac-P® +ER; SCOURMUNE®; PRV/MARKER GOLD®; PRV/MARKERGOLD®; MAXIVAC-FLU® (Schering Plough Animal Health Corporation);SUVAXYN® RESPIFEND® MH; SUVAXYN® MH-one; SUVAXYN® RESPIFEND® MH/HPS;SUVAXYN® RESPIFEND® HPS; SUVAXYN® RESPIFEND® APP; SUVAXYN® SIV/MH-one;SUVAXYN® SIV (H1N1 and H3N2); SUVAXYN®P; SUVAXYN® PLE; SUVAXYN® PLE+B;SUVAXYN® LE+B; SUVAXYN® PLE/PRVgpl⁻; SUVAXYN® PLE+B/PRVgpI; SUVAXYN®PRVgpl⁻; SUVAXYN® EC-4; SUVAXYN® E; SUVAXYN® E-oral (Fort Dodge AnimalHealth); ENDOVAC-PORCI® (Immvac, Inc.); ANTITOX TET™; DENAGARD®; MYCOSHIELD™; PARVO SHIELD® L5E; PNEUMOSTAR® Myco; PNEUMOSTAR® SIV; PORCINEPILI SHIELD™+C; PREFARROW SHIELD™ 9; RHINICELL® 1-D; RHINI SHIELD™ TX4;SALMO SHIELD® Live (Novartis Animal Health); Breed Sow 6; Breed Sow 7; EColicin S 3; E Colicin S 3+C; Erysipelas Bacterin; Lepto 5; Swine MasterM Plus (AgriLabs).

A further aspect relates to a container that comprises at least one doseof the L intracellularis antigen and at least one dose of the furtherimmunological active component of one or more of other swine pathogensas listed above. Preferably that container comprises at least one doseof the L intracellularis antigen and at least one dose of theimmunological active components according to any one of [combo 1] to[combo 775] as described above. Preferably, said container comprises 1to 250 doses each of the L intracellularis antigen and the immunologicalactive components according to any one of [combo 1] to [combo 775] asdescribed above. Preferably it contains 1, 10, 25, 50, 100, 150, 200, or250 doses each of the L intracellularis antigen and the immunologicalactive components according to any one of [combo 1] to [combo 775].Preferably, each of the containers further comprises ananti-microbiological active agent. Those agents are for exampleantibiotics including Gentamicin and Merthiolate and the like.

The present invention also relates to a kit, that comprises L.intracellularis antigen and the further immunological active componentsof one or more of the other swine pathogens as listed. Preferably thekit comprises L. intracellularis antigen and the further immunologicalactive components according to any one of [combo 1] to [combo 775].

The present invention also relates to a kit, that comprises L.intracellularis antigen and the further immunological active componentsof one or more of the other swine pathogens as listed in one container.Preferably, the kit comprises L. intracellularis antigen and the furtherimmunological active components according to any one of [combo 1] to[combo 775] in one container. According to a further aspect, the presentinvention also relates to a kit that comprises L. intracellularisantigen and the further immunological active components of one or moreof the other swine pathogens as listed in two or more containers.Preferably, the kit comprises L. intracellularis antigen and the furtherimmunological active components according to any one of [combo 1] to[combo 775] in two or more containers. For example, L. intracellularisantigen may be provided in one container, and the further immunologicalactive components, preferably any one of [combo 1] to [combo 775] may beprovide in a separate container. Both containers are part of the kit. Itis within the meaning of the present invention, that each container mayinclude a mixture of L. intracellularis antigen, a mixture of at leastof one but not all of the further immunological active components,preferably any one of [combo 1] to [combo 775], or a mixture of L.intracellularis antigen and at least of one but not all of the furtherimmunological active components, preferably any one of [combo 1] to[combo 775]. The missing immunological active component(s) of thatcombination vaccine is then provided in one or more separate containers,which all are part of the kit. Thus, the combination vaccines asprovided herewith can be provided as a multivalent vaccine thatcomprises all antigenic components in a single container, or in parts ofa kit in form of separate containers, that comprise the L.intracellularis antigen and the immunological active components of anyfurther swine pathogen as listed above, preferably according to any oneof [combo 1] to [combo 775], in at least to separate containers.

A further aspect of the present invention relates to a kit, thatcomprises any of the containers described above, and an instructionmanual, including the information for the administration of the Lintracellularis antigen and at least one dose of the immunologicalactive components according to any one of [combo 1] to [combo 775] asdescribed above. Moreover, according to a further aspect, saidinstruction manual comprises the information of a repeatableadministration of at least one dose of said combination vaccines.According to a further aspect, said instruction manual also includes theinformation, to administer an immune stimulant prior to orsimultaneously with the combination vaccine. This is preferablydesirable when the combination vaccine consists of killedmicroorganisms, or parts of microorganisms, or a combination thereof.Preferably, said immune stimulant shall be given at least twice. Apreferred immune stimulant is for example is keyhole limpet hemocyanin(KLH), still preferably emulsified with incomplete Freund's adjuvant(KLH/ICFA). However, it is herewith understood, that any other immunestimulant known to a person skilled in the art can also be used “Immunestimulant” as used herein, means any agent or composition that cantrigger the immune response, preferably without initiating or increasinga specific immune response, for example the immune response against aspecific pathogen. It is further instructed to administer the immunestimulant in a suitable dose. According to a further aspect, theinstruction manual comprises the information that all feed or otherwiseadministered antimicrobials shall be withheld around the time ofvaccination, preferably at least 3 to 4 days prior to vaccinationthrough 7 to 14 days post-vaccination. If the immunological activecomponents, including the L. intracellularis antigen of the vaccines aredehydrated, e.g. by lyophilization, the container further comprises asuitable reconstituent, preferably in form of a physiologicallyacceptable solution. Preferably, it further comprises means, e.g. asyringe for reconstitution and/or administration.

Formulations

A further important aspect of the present invention is the preparationof the combination vaccine(s). The skilled person knows additionalcomponents which may be comprised in said composition (see alsoRemington's Pharmaceutical Sciences. (1990). 18th ed. Mack Publ.,Easton). The expert may use known injectable, physiologically acceptablesterile solutions. For preparing a ready-to-use solution for parenteralinjection or infusion, aqueous isotonic solutions, such as e.g. salineor corresponding plasma protein solutions are readily available. Thepharmaceutical compositions may be present as lyophylisates or drypreparations, which can be reconstituted with a known injectablesolution directly before use under sterile conditions, e.g. as a kit ofparts.

In addition, the immunogenic and vaccine compositions of the presentinvention can include one or more veterinary-acceptable carriers. Asused herein, “a veterinary-acceptable carrier” includes any and allsolvents, dispersion media, coatings, adjuvants, stabilizing agents,diluents, preservatives, antibacterial and antifungal agents, isotonicagents, adsorption delaying agents, and the like.

“Diluents” can include water, saline, dextrose, ethanol, glycerol, andthe like. Isotonic agents can include sodium chloride, dextrose,mannitol, sorbitol, and lactose, among others. Stabilizers includealbumin and alkalisalts of ethylendiamintetracetic acid, among others.

Adjuvants” as used herein, can include aluminum hydroxide and aluminumphosphate, saponins e.g., Quil A, QS-21 (Cambridge Biotech Inc.,Cambridge Mass.), GPI-0100 (Galenica Pharmaceuticals, Inc., Birmingham,Ala.), water-in-oil emulsion, oil-in-water emulsion,water-in-oil-in-water emulsion. The emulsion can be based in particularon light liquid paraffin oil (European Pharmacopea type); isoprenoid oilsuch as squalane or squalene; oil resulting from the oligomerization ofalkenes, in particular of isobutene or decene; esters of acids or ofalcohols containing a linear alkyl group, more particularly plant oils,ethyl oleate, propylene glycol di-(caprylate/caprate), glyceryltri-(caprylate/caprate) or propylene glycol dioleate; esters of branchedfatty acids or alcohols, in particular isostearic acid esters. The oilis used in combination with emulsifiers to form the emulsion. Theemulsifiers are preferably nonionic surfactants, in particular esters ofsorbitan, of mannide (e.g. anhydromannitol oleate), of glycol, ofpolyglycerol, of propylene glycol and of oleic, isostearic, ricinoleicor hydroxystearic acid, which are optionally ethoxylated, andpolyoxypropylene-polyoxyethylene copolymer blocks, in particular thePluronic products, especially L121. See Hunter et al., The Theory andPractical Application of Adjuvants (Ed.Stewart-Tull, D. E. S.).JohnWiley and Sons, NY, pp 51-94 (1995) and Todd et al., Vaccine15:564-570 (1997). (The teachings and content of which are herebyincorporated by reference.)

For example, it is possible to use the SPT emulsion described on page147 of “Vaccine Design, The Subunit and Adjuvant Approach” edited by M.Powell and M. Newman, Plenum Press, 1995, and the emulsion MF59described on page 183 of this same book. (The teachings and content ofwhich are hereby incorporated by reference.)

A further instance of an adjuvant is a compound chosen from the polymersof acrylic or methacrylic acid and the copolymers of maleic anhydrideand alkenyl derivative. Advantageous adjuvant compounds are the polymersof acrylic or methacrylic acid which are cross-linked, especially withpolyalkenyl ethers of sugars or polyalcohols. These compounds are knownby the term carbomer (Phameuropa Vol. 8, No. 2, June 1996). Personsskilled in the art can also refer to U.S. Pat. No. 2,909,462 whichdescribes such acrylic polymers cross-linked with a polyhydroxylatedcompound having at least 3 hydroxyl groups, preferably not more than 8,the hydrogen atoms of at least three hydroxyls being replaced byunsaturated aliphatic radicals having at least 2 carbon atoms. Thepreferred radicals are those containing from 2 to 4 carbon atoms, e.g.vinyls, allyls and other ethylenically unsaturated groups. Theunsaturated radicals may themselves contain other substituents, such asmethyl. The products sold under the name Carbopol; (BF Goodrich, Ohio,USA) are particularly appropriate. They are cross-linked with an allylsucrose or with allyl pentaerythritol. Among then, there may bementioned Carbopol 974P, 934P and 971P. Most preferred is the use ofCarbopol 971P. Among the copolymers of maleic anhydride and alkenylderivative, the copolymers EMA (Monsanto) which are copolymers of maleicanhydride and ethylene. The dissolution of these polymers in water leadsto an acid solution that will be neutralized, preferably tophysiological pH, in order to give the adjuvant solution into which theimmunogenic, immunological or vaccine composition itself will beincorporated.

Further suitable adjuvants include, but are not limited to, the RIBIadjuvant system (Ribi Inc.), Block co-polymer (CytRx, Atlanta Ga.),SAF-M (Chiron, Emeryville Calif.), monophosphoryl lipid A, Avridinelipid-amine adjuvant, heat-labile enterotoxin from E. coli (recombinantor otherwise), cholera toxin, IMS 1314 or muramyl dipeptide among manyothers.

Preferably, the adjuvant is added in an amount of about 100 μg to about10 mg per dose. Even more preferably, the adjuvant is added in an amountof about 100 μg to about 10 mg per dose. Even more preferred theadjuvant is added in an amount of about 500 μg to about 5 mg per dose.Even more preferred the adjuvant is added in an amount of about 750 μgto about 2.5 mg per dose. Most preferred the adjuvant is added in anamount of about 1 mg per dose.

The vaccine composition can further include one or more otherimmunomodulatory agents such as, e.g., interleukins, interferons, orother cytokines. The vaccine compositions can also include Gentamicinand Merthiolate. While the amounts and concentrations of adjuvants andadditives useful in the context of the present invention can readily bedetermined by the skilled artisan, the present invention contemplatescompositions comprising from about 50 ug to about 2000 ug of adjuvantand preferably about 250 ug/ml dose of the vaccine composition. Inanother preferred embodiment, the present invention contemplates vaccinecompositions comprising from about 1 ug/ml to about 60 ug/ml ofantibiotics, and more preferably less than about 30 ug/ml ofantibiotics.

According to a further embodiment the combination vaccine is firstdehydrated. If the composition is first lyophilized or dehydrated byother methods, then, prior to vaccination, said composition isrehydrated in aqueous (e.g. saline, PBS (phosphate buffered saline)) ornon-aqueous solutions (e.g. oil emulsion (mineral oil, orvegetable/metabolizable oil based/single or double emulsion based),aluminum-based, carbomer based adjuvant).

As described above, the L intracellularis antigen and any furtherimmunological active components according to any one of [combo 1] to[combo 774] can be formulated as mono or multivalent formulations,whereas multivalent formulations are preferred. In the event, severalmono and or multivalent formulations are prepared, it is preferred topackage all components of the combination vaccine in one kit.

Dosage and Administration

According to the present invention, an effective amount of a combinationvaccine administered to pigs provides effective immunity againstmicrobiological infections or a decreased incidence of or severity ofclinical signs caused by L. intracellularis and at least one furtherpathogen as listed above. Preferred combinations of antigens for thetreatment and prophylaxis of microbiological diseases in pigs are listedabove.

The combination vaccines according to the invention are generallyadministered to susceptible animals, preferably swine, in one or moredoses. Live or killed vaccine may be administered 1 or 2 times at 2 to 4week intervals. For the attenuated, live vaccines, one dose ispreferred. Preferably, the first or single administration is performedwhen the animal is about 2 to 3 weeks to about 8 weeks of age. If asecond administration is desirable or necessary, the secondadministration is performed about 1 to about 4 weeks after the firstadministration of the vaccine. According to a further aspect,revaccination is performed in an interval of 3 to 12 month afteradministration of any previous vaccination. Administration of subsequentvaccine doses is preferably done on an 6 month to an annual basis. Inanother preferred aspect, animals vaccinated before the age of about 2to 3 weeks should be revaccinated. Administration of subsequent vaccinedoses is preferably done on an annual basis.

The amount of combination vaccine that is effective depends on theingredients of the vaccine and the schedule of administration.Typically, when an inactivated virus or a modified live viruspreparation is used in the combination vaccine, an amount of the vaccinecontains about 10² to about 10⁹ TCID50 per dose, preferably about 10³ toabout 10⁸ TCID50 per dose, more preferably, about 10⁴ to about 10⁸TCID50 per dose. In general, inactivated antigen is normally used inhigher amounts than live modified viruses.

Typically, when bacterial antigen is used in the combination vaccine,the vaccine contains an amount of about 10³ to about 10⁹ colony formingunits (CFU) per dose, preferably, about 10⁴ to about 10⁸ (CFU) per dose,more preferably about 10⁵ to about 10⁶ (CFU) per dose.

In particular, when modified live L. intracellularis bacteria are usedin the combination vaccines, e.g. the bacteria isolates designatedisolate B3903, ATCC accession No. PTA-4926 and designated isolateN34NP40wk, ATCC accession No. 55783 (both described in WO 96/39629 andWO 05/011731), the recommended dose to be administered to thesusceptible animal is preferably about 3.0 TCID₅₀ (tissue cultureinfective dose 50% end point)/dose to about 6.0 TCID₅₀/dose and morepreferably about 4.0 TCID₅₀/dose to about 5.0 TCID₅₀/dose. In apreferred embodiment, the titer of the vaccine is about 4.9 TCID₅₀/doseas determined by Tissue Culture Infective Dose 50% endpoint dilutionassay (TCID₅₀). In general, the quantity of immunogen will be between 5and 5000 micrograms, and between 10^(2.0) and 10^(9.0) TCID₅₀,preferably between 10^(3.0) and 10^(6.0) TCID₅₀, more preferably between10^(4.0) and 10^(5.0) TCID₅₀, when purified bacteria are used.

In particular, when Erysipelothirx rhusiopathiae is used in thecombination vaccines, e.g. in form of INGELVAC® Ery-ALC, the recommendeddose to be administered to the susceptible animal is preferably about1×10^(8.0) CFU (colony form units)/dose to about 1×10^(10.5) CFU/doseand more preferably about 1×10^(9.0) CFU/dose to about 9×10^(9.0)CFU/dose.

In particular, when Salmonella spp., in particular avirulent S.cholerasius is used in the combination vaccines, e.g. in form ofENTERISOL® SC54FF, the recommended dose to be administered to thesusceptible animal is preferably about 1×10^(7.0) CFU (colony formunits)/dose to about 1×10^(9.0) CFU/dose and more preferably about1×10^(8.0) CFU/dose to about 6×10^(8.0) CFU/dose.

Sub-unit vaccines are normally administered with an antigen inclusionlevel of at least 0.2 μg antigen per dose, preferably with about 0.2 toabout 400 μg/dose, still more preferably with about 0.3 to about 200μg/dose, even more preferably with about 0.35 to about 100 μg/dose,still more preferably with about 0.4 to about 50 μg/dose, still morepreferably with about 0.45 to about 30 μg/dose, still more preferablywith about 0.6 to about 15 μg/dose, even more preferably with about 0.75to about 8 μg/dose, even more preferably with about 1.0 to about 6μg/dose, still more preferably with about 1.3 to about 3.0 μg/dose.

The composition according to the invention may be applied intradermally,intratracheally, or intravaginally. The composition preferably may beapplied intramuscularly or intranasally. In an animal body, it can proveadvantageous to apply the pharmaceutical compositions as described abovevia an intravenous or by direct injection into target tissues. Forsystemic application, the intravenous, intravascular, intramuscular,intranasal, intraarterial, intraperitoneal, oral, or intrathecal routesare preferred. A more local application can be effected subcutaneously,intradermally, intracutaneously, intracardially, intralobally,intramedullarly, intrapulmonarily or directly in or near the tissue tobe treated (connective-, bone-, muscle-, nerve-, epithelial tissue).Depending on the desired duration and effectiveness of the treatment,the compositions according to the invention may be administered once orseveral times, also intermittently, for instance on a daily basis forseveral days, weeks or months and in different dosages.

The vaccine compositions as provided herein are intended to be used asan immunogen in antimicrobial vaccines for pigs. However, whereapplicable, the vaccine compositions provided herewith can also be usedfor the treatment and prophylaxis of other animals, including birds,fish, and mammals such as cattle, horses, and primates.

Methods for Treatment

Yet another important aspect of the invention is a method for theprophylaxis or treatment of diseases and/or lessening of the clinicalsigns caused by L. intracellularis, and one or more other swinepathogenic microorganism(s), wherein L. intracellularis antigen isadministered to a non-human animal in need thereof together with afurther immunological active components effective for the treatmentand/or prophylaxis of the infection caused by said other swinepathogenic microorganism. Relevant swine pathogenic microorganisms aswell as preferred combination vaccines that can be used are thosedescribed above. According to a further aspect, the L. intracellularisantigen and at least one further immunological active componenteffective for the treatment and/or prophylaxis and/or a lessening of theclinical signs of the infection caused by another swine pathogenicmicroorganism other than L. intracellularis are administered in form ofa single vial mixed formulation. Most preferred, all antigeniccomponents, including the L. intracellularis antigen of those vaccinesare mixed together in form of a single vial mixture. However, accordingto a further aspect of the method of treatment, the L. intracellularisantigen and one or more of the additional immunological activecomponents effective for the treatment and/or prophylaxis ofinfection(s) caused by one or more other swine pathogenic microorganismsother than L. intracellularis are administered in the form of separatesingle vial formulations, that are administered separately at leastwithin one week, preferably within 2 to 5 days, more preferably at 1day, even more preferably within 12 hours, even more preferably within 6hours, even more preferably within 3 hours, most preferably within 1hour.

All publications and patents cited herein are incorporated by referencein their entireties.

The present invention is further described in the following exampleswhich are provided for illustrative purposes only and are not to beconstrued as limiting. Indeed, other variants of the invention will bereadily apparent to one of ordinary skill in the art.

EXAMPLES Efficacy of a Combination Vaccine Comprising Lawsoniaintracellularis, Erysipelothrix Rhusiopathiae and Salmonella cholerasuisAntigen

Test Substance(s):

Lawsonia intracellularis Vaccine, Avirulent Live Culture, trade nameENTERISOL® Ileitis FF, Product Code 10L1.00; Lawsonia intracellularisVaccine, Avirulent Live Culture, trade name ENTERISOL® IleitisLyophilized, Product Code 10L1.01; Erysipelothrix rhusiopathiae Vaccine,Live Culture, trade name INGELVAC® Ery-ALC, Product Code 1541.00;Salmonella cholerasuis Vaccine, Avirulent Live Culture, trade nameENTERISOL® SC-54FF, Product Code 19A1.00. All products are registeredfor Boehringer Ingelheim Vetmedica, Inc., St. Joseph, Mo., U.S.

Formulation

The test articles were combination vaccines consisting of 1 ml v/v eachof ENTERISOL® Ileitis (FF or LYO)-ENTERISOL® SC-54, FF-INGELVAC® ERY-ALCFF. Three vials of each vaccine component were pooled individually. TheERY component was used in the vaccine formulations undiluted. The L.intracellularis, FF and LYO, and SC-54 components were diluted as shownbelow before addition to the final vaccine formulation.

L. intracellularis, FF dilution: 2.5 ml bacterin in 97.5 ml growthmedium (1:40) L. intracellularis, LYO dilution: 31.6 ml bacterin in 68.4ml growth medium (1:3.2) SC-54 dilution: 50 ml bacterin in 250 ml PBS(1:6)

The final vaccines were formulated with equal volumes of the threecomponents

A. Efficacy of the L. intracellularis Component

The objectives of the study were to demonstrate the efficacy of thelyophilized and frozen forms of the Lawsonia intracellularis antigen inyoung pigs when given in combination with Erysipelothrix rhusiopathiaeantigen and Salmonella cholerasuis antigen and lack of interference bythe Erysipelothrix rhusiopathiae antigen and Salmonella cholerasuisantigen on the efficacy of the Lawsonia intracellularis antigen.

Experimental Design:

The study consisted of 4 treatment groups of weaned 3 week old (+/−5days) L. intracellularis-negative test pigs. All vaccinations were givenon day 0 of the study. Treatment group 1 (n=20) will receive a targetdose of 1×10^(4.9) TCID₅₀/dose of ENTERISOL® Ileitis (FF) in combinationwith INGELVAC® ERY-ALC (9×10⁹ cfu/dose) and ENTERISOL® SC-54 (FF) (4×10⁸cfu/dose) via oral drench. Treatment group 2 (n=20) will receive atarget dose of 1×10^(4.9) TCID₅₀/dose of ENTERISOL® Ileitis lyophilizedin combination with INGELVAC® ERY-ALC (9×10⁹ cfu/dose) and ENTERISOL®SC-54 (FF) (4×10⁸ cfu/dose) via oral drench. Treatment group 3 (n=20)are designated as study “challenge controls” and did not receive avaccination but were given an equivalent volume of placebo via oraldrench.

Treatment group 4 (n=10) are designated as study “Strict Controls” anddid not receive a vaccine or placebo treatment or challenge.

On day 23 of the study, treatment groups 1, 2 and 3 (20 pigs each)received a target dose of greater than 1×10^(7.0) TCID₅₀ of heterologousvirulent low passage pure culture challenge material (L.intracellularis) by gavage. Three weeks after challenge administration(day 43), all treatment groups (1 through 4) were euthanized andnecropsied for gross and microscopic analysis for lesions from PPE.

Results

Gross Lesions

At necropsy, a section of the intestinal tract approximately 1 meterlong containing segments of the ileum, cecum and colon was removed fromeach pig and examined for gross lesions. The lesions were scored byseverity and the ileal-cecal junction was removed forimmunohistochemistry (IHC) staining. Table 1, below shows the averagelesion scores for treatment group by lesion site and the number ofanimals with a positive score per group. Treatment group 4, strictcontrols are included in this table because 2 of the 10 animals did havemild lesion scores characterized by redness and slight swelling in thecolon.

TABLE 1 Average gross lesion scores by treatment group and number ofanimals with a positive score within groups. Overall # ‘+’/ Ileum CecumColon group group Group ID Treatment score score score score total 1FF-combo 0.2 0 0.1 0.3^(a)  5/20^(a) 2 Lyo-combo 0.3 0 0 0.3^(a) 4/20^(a) 3 Controls 1.2 0.4 0.3 1.9^(b) 13/18^(b) 4 Strict controls 0 00.2 0.2  2/10 ^(a,b)Scores with different letters denote statisticallysignificant differences (p ≤ 0.05). Strict controls were not part of thestatistical analysis.

Statistical analyses were run on individual site scores, overall scoresand positive animals per treatment group. There was a statisticallysignificant difference between vaccinates in treatment groups 1 and 2versus the controls for gross lesion scores overall and by treatmentgroup (p<0.0001). There was also a significant difference betweenvaccinates versus controls in number of positive animals (p<0.0001).There was no significant difference between treatment groups 1 and 2.

Microscopic Lesions

Table 2, below, shows the microscopic lesion data by treatment group.Note that treatment group 4 had no samples positive for L.intracellularis.

TABLE 2 Average IHC scores for microscopic lesions by treatment group.Small Large Small Small intestine Large Large intestine # ‘+’/ Groupintestine intestine IHC intestine intestine IHC group ID Treatment siteslesions positive sites lesions positive total 1 FF-combo 0.4 0.3 0.350.1 0.05 0.05 5/20 2 Lyo- 0.45 0.40 0.30 0.25 0.15 0.15 6/20 combo 3Controls 0.56 0.39 0.39 0.22 0.22 0.28 6/18 4 Strict 0 0 0 0 0 0 0/10controls

The control group did show higher microscopic lesion scores with morepositive animals than either vaccinate group but the differences notedwere not statistically significant (p>0.05).

Conclusion

The results of this study demonstrate that the combination of INGELVAC®ERY-ALC, ENTERISOL® SC-54 with ENTERISOL® Ileitis, ALC does not causeinterference with the Lawsonia fraction of the vaccine. Both the frozenand lyophilized forms of the vaccine significantly reduced intestinallesions caused by Lawsonia intracellularis in this vaccination/challengestudy. No interference by the Erysipelothrix and Salmonella vaccines onthe efficacy of the Lawsonia vaccine was observed in this study

B. Efficacy of the Erysipelothrix Rhusiopathiae Component

The objectives of the study were to demonstrate the efficacy of thelyophilized and frozen forms of the Erysipelothrix rhusiopathiae antigenin young pigs when given in combination with Lawsonia intracellularisantigen and Salmonella cholerasuis antigen and lack of interference bythe Lawsonia intracellularis antigen and Salmonella cholerasuis antigenon the efficacy of the Erysipelothrix rhusiopathiae antigen.

Experimental Design:

This study consisted of four groups with 15 animals in each of groups 1,2, and 3, and five animals in group 4. Group 1 was vaccinated with theINGELVAC® Ery-ALC (9×109 cfu/dose), ENTERISOL® SC-54 6.9×108 cfu/dose)and ENTERISOL® Ileitis 1×106.1 TCID50/dose), combination via oral drenchon day 0. Group 2 was vaccinated with INGELVAC® Ery-ALC (9×109 cfu/dose)only via oral drench on day 0. Groups 3 and 4 served as challengecontrols and strict controls, respectively.

Pigs in groups 1, 2, and 3 were challenged with virulent E.rhusiopathiae, strain E-1-6 on day 21 by intramuscular injection in theham muscle (4×104 cfu/dose.). Animals were observed daily for clinicalsigns, lesions, or elevated temperatures associated with Erysipelas. Allanimals were euthanized seven days post challenge. Pigs that displayedclinical signs and/or elevated temperatures were necropsied. Kidney andspleen samples were collected in an attempt to determine if the cause ofthe clinical lesions and/or elevated temperatures was due to anErysipelas infection.

Results

Clinical Observations:

Daily clinical observations were made from Trial Day 19 (−2 DPC) throughTrial Day 28 (7 DPC). There were no clinical symptoms seen in the groupgiven the combination vaccine. Only one of fifteen (6.7%) animals thatreceived INGELVAC® Ery-ALC only became lethargic and had a lesion thatwas red and raised. In contrast, all of the challenge control animalswere affected by the challenge, with symptoms including rapidrespiration, lethargy, red and raised lesions, and lameness. There wasalso a 33% mortality rate in the challenge control group with deathoccurring in 5 of 15 animals.

TABLE 3 Clinical Signs # of animals Bacterial Isolation Treatment Groupaffected (% Positive) Mortality Ery/SC-54/Ileitis 0/15 (0%) N/A 0/15(0%) INGELVAC ® Ery- 1/15 (6.7%) 1/1 (100%) 0/15 (0%) ALC ChallengeControls 15/15 (100%) 13/15 (86.7%) 5/15 (33.3%) Strict Controls 0/5(0%) N/A 0/5 (0%)

Post Challenge Organ Culture:

At study termination, the animals were euthanized, and those affectedwith clinical signs of erysipelas were necropsied, and the kidney andspleen were cultured for the presence of Erysipelothrix. E.rhusiopathiae was recovered from 13 of 15 of the animals in thechallenge control group, and from the one animal in the INGELVAC®Ery-ALC group.

TABLE 4 Results of the post challenge organ culture SC-54/Ery INGELVAC ®Challenge Strict Parameters Ileitis Ery-ALC Controls Controls Clin Score(% 0 6.7 100 0 affected) % Mortality 0 0 33.3 0 Bacterial Isola- N/A 6.786.7 N/A tion (% Pos) Avg. Temps (F.) 103.7 103.5 104.7 103.2

Conclusion:

The combination of INGELVAC® Ery-ALC, ENTERISOL® SC-54, and ENTERISOL®Ileitis, ALC proved to be efficacious against an E. rhusiopathiaechallenge and, therefore proves that there is no interference from theENTERISOL® SC-54 and ENTERISOL® Ileitis vaccines.

C. Efficacy of the Salmonella Cholerasuis Component

The objectives of the study were to demonstrate the efficacy of thelyophilized and frozen forms of the Salmonella cholerasuis antigen inyoung pigs when given in combination with Lawsonia intracellularisantigen and Erysipelothrix rhusiopathiae antigen and lack ofinterference by the Lawsonia intracellularis antigen and Erysipelothrixrhusiopathiae antigen on the efficacy of the Salmonella cholerasuisantigen.

Experimental Design:

This study consisted of four groups with 15 animals in groups 1, 2, and3, and five animals in group 4. Pigs in group 1 were vaccinated with theINGELVAC® Ery-ALC (3.3×10¹⁰ logs/dose), ENTERISOL® SC-54 (2.8×10⁸logs/dose) and ENTERISOL® Ileitis (6.1 logs/dose) combination via oraldrench on day 0. Pigs in group 2 were vaccinated with ENTERISOL® SC-54only via oral drench on day 0. Pigs in groups 3 and 4 did not receivevaccine treatment and served as challenge and strict controls,respectively.

Pigs in groups 1, 2, and 3 were challenged with virulent Salmonellacholerasuis, Strain 38, intranasally on day 28 (2.93×10⁹ cfu/dose).Fecal swabs were collected daily following challenge and cultured forSalmonella sp. Animals were weighed at the time of vaccination,challenge, and necropsy. Body temperatures were monitored for two daysprior to challenge and daily following challenge. The clinical health ofeach animal was monitored daily for the duration of the study. At thetermination of the study (day 41), pigs were euthanized and organs(tonsil, lung, liver, spleen, mesenteric lymph node (MLN), ileum, andcolon) were collected and cultured for the presence of Salmonella sp.

Results:

INGELVAC® Ery-ALC and ENTERISOL® Ileitis vaccines were used according tolabel recommended dosage, and the ENTERISOL® SC-54 vaccine was dilutedto the minimum immunizing dose, 2.8×10⁸ cfu/mL, prior to administration.General observations were made from vaccination to challenge.Clinically, both vaccinated groups (combination and ENTERISOL® SC-54only) performed well against the virulent Salmonella cholerasuischallenge, with significant (P<0.05) reductions in rectal temperatures,clinical symptoms, and increased weight gains in comparison to thechallenge controls. There were notable differences between vaccinatedand challenge control groups in the culture results. Both vaccinatedgroups had reduced amounts of fecal shedding (8.1%-combo, 11.4%-SC-54)as compared to the challenge controls (24%), with significant (P<0.05)reductions of the number of animals shedding the bacteria in the last 5days of the 13-day observation period. Salmonella cholerasuis wasrecovered from all tissues in the ENTERISOL® SC-54 vaccinate andchallenge control groups, but only from four of the seven tissues ineach vaccinate of the combination vaccinate group. In addition, therewas a significant (P<0.05) reduction in the recovery of bacteria fromthe MLN and colon from pigs in both vaccinated groups compared to thechallenge control group.

TABLE 5 Results Summary Table Salm/Ery Salmonella Challenge StrictParameters Lawsonia Only Controls Controls Mean Clinical Scores 10.2610.34 10.28 10.02 # days significantly 3 days 2 days N/A 2 days (P <0.05) different (31, 39, (39 and 40) (31 and from Challenge Con- & 40)39) trols (post-challenge) Mean Rectal Temps 103.7 103.9 104.5 103.2 (°F.) # days significantly 10 days 8 days N/A 10 days (P < 0.05) different(31-41) (32-39) (29-38) from Challenge Con- trols (post-challenge)Average Daily Weight 0.84^(a,b) 1.00^(a) 0.60^(b) 1.54^(c) Gain (lbs/daypost- challenge) Fecal Culture (% Pos) 8.1 11.4 24 1.7 Tissue Culture (%Pos) 9.5 17.1 35.7 0 ^(a,b)= Like letters are not statistically (P <0.05) different.

Conclusion:

The combination of INGELVAC® Ery-ALC, ENTERISOL® SC-54, and ENTERISOL®Ileitis proved to be efficacious against a virulent Salmonellacholerasuis challenge. Therefore, this study demonstrates that there isno interference of the Ery-ALC and Ileitis-ALC vaccines to the SC-54vaccine.

What is claimed:
 1. A method for inducing an immune response againstLawsonia intracellularis bacterium to protect against porcineproliferative enteropathy (PPE) and an immune response against at leastone additional pathogenic swine microorganism, comprising: administeringto a non-human animal a pharmaceutical composition comprising antigenswhich consist essentially of: (i) killed Lawsonia intracellularisbacterium, (ii) killed Mycoplasma hyopneumoniae, and (iii) Porcinecircovirus.
 2. The method of claim 1, wherein the pharmaceuticalcomposition is administered in one dose.
 3. The method of claim 1,wherein the pharmaceutical composition is administered in multipledoses.
 4. The method of claim 3, wherein a first dose of thepharmaceutical composition is administered when the non-human animal isabout 2 to about 8 weeks of age.
 5. The method of claim 4, wherein asecond dose of the pharmaceutical composition is administered about 1 to4 weeks after the first dose.
 6. The method of claim 1, wherein thepharmaceutical composition contains 10<2> to 10<9> TCID50 of eachantigen.
 7. The method of claim 1, wherein the pharmaceuticalcomposition comprises between 5 and 5000 micrograms of each antigen. 8.The method of claim 1, wherein the pharmaceutical composition furthercomprises a pharmaceutically acceptable carrier.
 9. The method of claim8, wherein the pharmaceutically acceptable carrier is an adjuvant. 10.The method of claim 9, wherein said adjuvant is selected from awater-in-oil emulsion, an oil-in-water emulsion, and awater-in-oil-in-water emulsion.
 11. The method of claim 2, wherein thepharmaceutical composition is administered when the non-human animal isabout 2 to about 8 weeks of age.